| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Emergent BioSolutions Inc.$8.05
+0.02 (+0.21%)
C 54Pipeline Score Undervalued Pharma · Commercial
Market Cap
435.99 M
EPS
-0.17
P/E Ratio
-
Value Trade
8.18 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
156.10 M
R&D Expenses
10.50 M
Operating CF
-33.80 M
Total Assets
1.32 B
Total Liabilities
797.30 M
Equity
523.10 M
D/E Ratio
12,345
4.32 %
Week
4.19 %
1 Month
-21.76 %
3 Month
-6.63 %
6 Month
-85.68 %
5 Year
-28.42 %
All Time
Cash Data
Cash Position
161.50 M
Monthly Burn
11.27 M
Runway
12.2 mo
Burn Trend
SEC Filing
May 1, 2026
Overview
Volume
1.21 M
52 Week Range
5.62 - 14.06
% held by Insiders
5.58 %
% held by Institutions
85.57 %
Enterprise Value
909.49 M
Total Shares
51.64 M
Short %
20.06 %
Float Shares
50.61 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Emergent BioSolutions Inc.
796Total events
5Upcoming
252Tier-1 (high impact)
2014 – 2027Coverage
Upcoming catalysts 5
TBD
T3Enrollment Update
Plan to extend study to new countries including Uganda and enroll patients to reach next milestone
Event history 791
Jun 2026
▲Other Regulator MilestoneACAM2000ApprovedEx-US Regulatory
Singapore HSA approved expanded indication for ACAM2000 to include prevention of mpox disease in high-risk adults
mpoxsource ↗
Jun 2026
▲Supply DisruptionACAM2000ApprovedCMC / Inspection
Contract modification valued at $52.7 million from ASPR to supply ACAM2000 vaccine, ancillaries, and diluent replacement lots
smallpox and mpoxsource ↗
Jun 8, 2026
May 28, 2026
▲Partnership / LicenseBAT®Corporate
Emergent receives $64.5 million contract modification from ASPR for BAT®
symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or Gsource ↗
May 28, 2026
◆Oral PresentationPresentation
Benchmark 6th Annual Healthcare House Call Virtual Investor Conference
May 27, 2026
◆Oral PresentationPresentation
Goldman Sachs 11th Annual Leveraged Finance and Credit Conference
May 18, 2026
▲Other Regulator MilestoneACAM2000ApprovedEx-US Regulatory
Singapore HSA approval for expanded indication to include mpox
mpoxsource ↗
Apr 30, 2026
▲Other Regulator MilestoneACAM2000ApprovedEx-US Regulatory
Singapore HSA approved expanded indication for ACAM2000 to include mpox
mpoxsource ↗
Apr 30, 2026
▲Partnership / LicenseSAB-142Corporate
Secured strategic manufacturing partnership with SAB Biotherapeutics for SAB-142
type 1 diabetessource ↗
Apr 30, 2026
▲Partnership / LicenseCorporate
Secured strategic manufacturing partnership with Substipharm Biologics for Japanese Encephalitis vaccine
Japanese Encephalitissource ↗
Drug Pipeline Intelligence
C54
Pipeline Score $1.6B
Pipeline ValueUndervalued
Valuation Signal28
Drugs Scored12.4x
rNPV / MCap Top 82%
Micro Cap (rank 165 of 911)
Percentile RankEmergent BioSolutions Inc. carries a moderate pipeline score (54/100), with $6.3B risk-adjusted pipeline value, led by COVID-HIG in SARS-CoV-2 Infection (Phase 1), across $169B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-HIG Monoclonal antibody | SARS-CoV-2 Infection | Phase 1 | NCT05142306 | 22% | $1.7B | COMPLETED | 23 | - | - | May 31, 2022 | - | Jun 8, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
COVID-HIG | COVID-19 | Phase 3 | 2021-04-02 | the addition of anti-SARS-CoV-2 hyperimmunoglobulin to standard of care, inclusive of remdesivir, for hospitalized adult COVID-19 patients with symptoms for less than 12 days did not provide clinical benefit when compared to standard of care plus placebo. Read More | Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19 Read More | |
COVID-HIG | COVID-19 | Phase 3 | 2021-04-02 | the addition of anti-SARS-CoV-2 hyperimmunoglobulin to standard of care, inclusive of remdesivir, for hospitalized adult COVID-19 patients with symptoms for less than 12 days did not provide clinical benefit when compared to standard of care plus placebo. Read More | Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19 Read More | |
COVID-HIG | COVID-19 | Phase 3 | 2021-04-02 | the addition of anti-SARS-CoV-2 hyperimmunoglobulin to standard of care, inclusive of remdesivir, for hospitalized adult COVID-19 patients with symptoms for less than 12 days did not provide clinical benefit when compared to standard of care plus placebo. Read More | Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EBS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EBS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EBSEmergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
Emergent BioSolutions has announced a contract modification worth $52.7 million from the U.S. government for its ACAM2000® vaccine, aimed at smallpox and mpox preparedness. Deliveries are set to begin shortly, reflecting ongoing government efforts in biodefense. The contract follows recent approvals of ACAM2000® in Saudi Arabia and Singapore for high-risk individuals.
Read more →EBS▲ +6.4%on this news
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Emergent BioSolutions is collaborating with Victoria's Voice Foundation to observe National Naloxone Awareness Day on June 6th, aiming to combat the opioid epidemic. Their campaign promotes naloxone accessibility and education through various initiatives, including distributing NARCAN® Nasal Spray. The event honors those lost to overdoses, especially Victoria Siegel, and emphasizes the importance of community preparedness. Future programs include outreach to colleges to further spread awareness and resources related to opioid overdose interventions.
Read more →EBSEmergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Emergent BioSolutions has received a $64.5 million contract modification from the ASPR to supply its Botulism Antitoxin Heptavalent (BAT®). This modification extends an existing contract and underscores the company's commitment to U.S. biodefense. The BAT® is crucial for treating symptomatic botulism in both adults and children following exposure to botulinum neurotoxin.
Read more →EBSEmergent BioSolutions to Participate in Upcoming Investor Conferences
Emergent BioSolutions Inc. will participate in several upcoming investor conferences, including the Goldman Sachs 11th Annual Leveraged Finance and Credit Conference and the Jefferies Global Healthcare Conference. These events will provide opportunities for the company's senior management to engage with investors and discuss their mission to protect public health. The presentations will be available via webcast.
Read more →EBSEmergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
Emergent BioSolutions has received approval from the Saudi Food and Drug Authority for its ACAM2000® vaccine, which is designed to prevent smallpox and mpox in high-risk individuals. This marks the first product from Emergent to be licensed by the SFDA. The approval follows a similar recent endorsement from Singapore's Health Sciences Authority. The vaccine addresses a critical public health threat amid rising global cases of mpox.
Read more →EBSEmergent BioSolutions Reports First Quarter 2026 Financial Results
Emergent BioSolutions Inc. reported its financial results for Q1 2026, with total revenues of $156.1 million, a decrease of 30% compared to the same period in 2025. The net income dropped significantly by 90% to $6.8 million, reflecting challenges in product sales, particularly in the Anthrax and Smallpox segments. However, the company highlighted the establishment of a strategic manufacturing partnership and efforts to maintain its market share in the NARCAN product line. Additionally, Emergent is working on refinancing its debt to enhance financial flexibility amidst ongoing operational transformations.
Read more →EBSDocument EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS First Quarter 2026 Total Revenues of $156.1 million First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% First Quarter 2026
Emergent BioSolutions Inc. (EBS) reported a total revenue of $156.1 million and a net income of $6.8 million for Q1 2026, reflecting a significant decline compared to the same quarter in 2025. The company experienced a 30% decrease in total revenues and a 90% drop in net income year-over-year. Despite these challenges, Emergent secured strategic manufacturing partnerships and maintained its market position with NARCAN Nasal Spray. The company is also progressing with a multi-year transformation plan aimed at enhancing its operational efficiency and financial stability.
Read more →EBSEmergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
Emergent BioSolutions has received approval from Singapore's Health Sciences Authority for an expanded indication of ACAM2000®, allowing its use for the prevention of mpox in high-risk adults. This decision is supported by safety data and an effective animal study. The approval aims to enhance public health preparedness during mpox outbreaks.
Read more →EBSEmergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
Emergent BioSolutions has entered a multi-year contract with SAB Biotherapeutics valued at approximately $50 million to support the development and manufacturing of SAB-142, a candidate for Type 1 Diabetes. The agreement includes end-to-end services compliant with good manufacturing practices and highlights the capabilities of Emergent's Winnipeg facility. This partnership aims to enhance the production of SAB-142 as it progresses through clinical trials.
Read more →EBSEmergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives
Emergent BioSolutions has partnered with baseball player Davis Schneider to raise awareness about NARCAN® Nasal Spray in Canada. Schneider shares his family's experience with opioid overdose to highlight the importance of being prepared. The initiative aims to combat the opioid crisis, which has claimed over 53,000 lives in Canada since 2016. NARCAN® can reverse opioid overdoses and is available at no cost in several provinces.
Read more →EBSEmergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
Emergent BioSolutions has entered a $34.5 million partnership with Substipharm Biologics to manufacture the Japanese Encephalitis vaccine, IMOJEV®, at its Canton facility. Emergent will also serve as the exclusive distributor of the vaccine to the U.S. government, pending FDA approval. This partnership aims to bolster U.S. preparedness against JE and enhance the vaccine's availability in the market.
Read more →EBSEmergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
Emergent BioSolutions Inc. will report its financial results for the first quarter of 2026 on April 30, 2026. A conference call is scheduled for 5:00 p.m. ET, where participants can join via webcast or telephone. The company emphasizes its mission to protect public health through various life-saving solutions.
Read more →EBSEmergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
Emergent BioSolutions has successfully refinanced its term loan and amended its asset-based revolving loan facility, enhancing its financial flexibility. The new $150 million term loan will replace the previous facility, while the amended loan increases borrowing capacity to $50 million. This strategic move aims to reduce interest expenses and support the company's multi-year transformation plan.
Read more →EBS▼ -5.8%on this news
Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program
Emergent BioSolutions has partnered with the B.C. Provincial Health Services Authority to supply NARCAN® Nasal Spray for the expanded Take-Home Naloxone Program in British Columbia. This initiative follows an $18 million CAD investment by the B.C. government to enhance opioid overdose response efforts. The program aims to increase access to life-saving naloxone across various community sites in the province.
Read more →EBSEmergent BioSolutions Launches New NARCAN Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
Emergent BioSolutions has launched a new carrying case for its NARCAN Nasal Spray and expanded the availability of multipacks to increase accessibility amidst an ongoing opioid epidemic. These initiatives are part of a broader campaign, which includes partnering with college campuses to educate students on the importance of preparedness for opioid overdoses. A recent survey highlighted the need for tools like the carrying case, which is tailored for easy transport and use. The campaign also features public figures to foster discussions surrounding mental health and stigma reduction associated with opioid overdose.
Read more →EBSEmergent BioSolutions Participates in Upcoming International Preparedness Conferences
Emergent BioSolutions Inc. will participate in several international preparedness conferences, including the London Defence Conference and the Global Health Security Conference. The company's teams aim to collaborate with government and industry leaders to enhance global health security. Emergent specializes in medical countermeasures to protect against various health threats.
Read more →EBSEmergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
Emergent BioSolutions has announced a contract worth approximately $54 million from the U.S. government for the delivery of Vaccinia Immune Globulin Intravenous (VIGIV) as part of smallpox preparedness. Additionally, the company received $6.6 million in new orders from an international partner for the ACAM2000 smallpox vaccine. These contracts highlight Emergent's ongoing commitment to biodefense and public health initiatives.
Read more →EBSEmergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
Emergent BioSolutions has appointed John D. Fowler, Jr. to its board of directors, effective March 1, 2026. Fowler, who has over 30 years of experience in healthcare and financial services, will also serve on the Audit and Finance Committee. His appointment is viewed as crucial for the company's ongoing transformation and strategic priorities.
Read more →EBSEmergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness
Emergent BioSolutions has announced new contracts with the Public Health Agency of Canada and the Department of National Defence, valued at approximately $140 million CAD. These agreements will support Canada's biological threat preparedness by providing critical medical countermeasures. The partnership emphasizes domestic production capabilities and aims to bolster Canada's resilience against biological threats. Emergent's innovative supply model is designed to enhance the preparedness and response capabilities of health agencies across the country.
Read more →EBSDocument EMERGENT BIOSO LUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS Fourth Quarter 2025 Total Revenues of $148.7 million Full Year 2025 Total Revenues of $742.9 million Fourth Quarter 2025 Net Los
Emergent BioSolutions has reported its financial results for Q4 and the full year 2025, showcasing a significant turnaround with a net income of $52.6 million, improving from a large net loss in the previous year. However, Q4 revenues fell by 24% to $148.7 million, primarily due to a decrease in naloxone product sales driven by increased competition. The company's adjusted EBITDA for the year reached $205 million, indicating improved operational efficiency and margin expansion. The company also plans to expand its market presence internationally and invest in future growth opportunities.
Read more →EBSEmergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
Emergent BioSolutions reported its financial results for Q4 and the full year 2025, showcasing substantial gains in net income and adjusted EBITDA. The company achieved a net income of $52.6 million for the year, a stark contrast to a net loss of $190.6 million in 2024. However, they reported a significant net loss of $54.6 million in Q4 2025, alongside a 24% revenue decline in the quarter. Despite these challenges, Emergent is focused on expanding its international market penetration and improving operational efficiencies.
Read more →EBSEmergent BioSolutions Announces New $50 Million Stock Repurchase Program
Emergent BioSolutions Inc. has announced a new stock repurchase program authorizing the buyback of up to $50 million in common stock before March 31, 2027, replacing its prior authorization. The previous program saw the company repurchase $24.8 million of its shares, indicating a commitment to shareholder value. CEO Joe Papa highlighted the firm’s confidence in achieving strong cash flow and successful capital allocation strategies aimed at growth and debt reduction. The timing for the new buybacks will depend on market conditions and other factors.
Read more →EBSEmergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Emergent BioSolutions Inc. will host a conference call on February 26, 2026, to discuss its financial results for the fourth quarter and full year of 2025. Participants can join via webcast or telephone after registering in advance. The company emphasizes its mission to protect public health through various life-saving solutions.
Read more →EBSEmergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN Nasal Spray Multipacks
Emergent BioSolutions has received FDA approval for a supplemental New Drug Application allowing for new multipack configurations of NARCAN Nasal Spray. The approved 6-count and 24-count multipacks aim to improve cost-effectiveness and distribution efficiency, supporting community programs dealing with opioid overdoses. This expansion complements previous product improvements, including the recent approval of a NARCAN Carrying Case. The multipacks will be available through Emergent's proprietary distribution platform, NARCANDirect.
Read more →EBSEmergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
Emergent BioSolutions has received approval from the U.S. FDA for a supplemental New Drug Application to package its NARCAN Nasal Spray in a new carrying case. The design aims to increase accessibility and encourage users to have the opioid reversal medication readily on hand during emergencies. Surveys indicate that a majority of consumers find the discreet carrying case preferable, especially among high-risk groups like college students. The new package will soon be available at select retailers and through the company's proprietary ordering platform, NARCANDirect.
Read more →EBSCombating Public Health Threats for Communities Around the World th 44 Annual J.P. Morgan Healthcare Conference Joe Papa President and Chief Executive Officer
At the 44th Annual J.P. Morgan Healthcare Conference, EBS President and CEO Joe Papa outlined the company's mission to protect public health through its biodefense and medical countermeasure products. EBS provided a revenue guidance of $775 million to $835 million for 2025 while detailing a multi-year transformation plan aimed at boosting shareholder value. However, the company also faces significant risks, including dependence on government contracts and potential competitive market pressures.
Read more →EBSEmergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
Emergent BioSolutions announced a voluntary prepayment of $100 million on its term loan, showcasing strong progress in its multi-year transformation plan. This move has contributed to a total gross debt reduction of $275 million, representing a 32% decline since 2023. The company aims to improve its financial position and support long-term growth strategies. CEO Joe Papa highlighted the importance of this milestone for enhancing financial flexibility.
Read more →EBSEmergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
Emergent BioSolutions has received a delivery order worth up to $21.5 million from the U.S. Department of War to supply BioThrax® (Anthrax Vaccine Adsorbed) in 2026. This order is part of an existing indefinite-delivery/indefinite-quantity contract and aims to protect military personnel at high risk of anthrax exposure. Deliveries will occur in 2026, with options for additional years.
Read more →EBSWashington My Health My Data Act Privacy Notice
Emergent BioSolutions has issued a privacy notice in compliance with Washington's My Health My Data Act, effective January 2026. The notice outlines how the company collects, uses, and shares consumer health data, emphasizing consumer rights and data protection measures. Key provisions include consent requirements, data access rights, and strict controls on data sharing.
Read more →EBSEmergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
Emergent BioSolutions has announced a partnership with PANTHER to extend funding for the Africa CDC-led MpOx Study, which seeks effective treatments for mpox. This study, initiated in 2024, is undergoing a double-blind clinical trial across multiple African nations. The independent data and safety monitoring board has endorsed the study's continuation after reviewing safety data with no concerns raised. As part of the initiative, additional sites, including one in Uganda, are to be established to enhance the trial's reach and impact.
Read more →EBS▲ +5.7%on this newsshared move
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Emergent BioSolutions Inc. has announced that CEO Joe Papa will present at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2026. The presentation will take place at 5:15 PM PST, and an audio link will be available for up to 30 days. Additionally, the presentation slides will be accessible on the company's Investor section at the time of the presentation.
Read more →EBSCountermeasures Season 3 Episode 6 Transcript: Impact of Climate Change on Health
The episode discusses the complex interplay between climate change and public health, highlighting the urgent challenges posed by rising temperatures, food insecurity, and health system resilience. Experts Kristie L. Ebi and Eloise Todd emphasize the need for proactive measures to address these issues, including urban planning and community engagement. They express hope in the growing awareness and commitment among young professionals to tackle these challenges.
Read more →EBSEmergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
Emergent BioSolutions announced that the U.S. FDA has approved its supplemental Biologics License Application for raxibacumab manufacturing at its facility in Winnipeg, Canada. This facility, with over 45 years of experience in therapeutic production, will now be a key site for raxibacumab, which is used for treating and preventing inhalational anthrax. The approval aligns with Emergent's broader transformation strategy aimed at consolidating manufacturing and enhancing operational efficiency. However, it's worth noting that raxibacumab's effectiveness has primarily been studied in animal models, and there are risks of hypersensitivity reactions associated with its use.
Read more →EBSCountermeasures Season 3 Episode 5 Transcript: Naloxone Access
The latest episode of Countermeasures discusses the opioid crisis and the critical role of naloxone in reducing overdose deaths. With the FDA's approval of NARCAN® Nasal Spray for over-the-counter sale, access to this life-saving medication has improved significantly. However, challenges such as stigma and inequitable distribution persist, particularly in marginalized communities. Experts emphasize the importance of continued education and community involvement in combating the crisis.
Read more →EBSCountermeasures Season 3 Episode 4 Podcast Transcript: Zoonotic Disease and Disease Surveillance
The podcast discusses the complexities of zoonotic diseases and the importance of effective disease surveillance. Experts emphasize the need for integrated health systems that encompass human, animal, and environmental health. They highlight the evolving nature of avian influenza and the critical role of early detection in preventing outbreaks. The conversation also addresses the challenges of funding and communication in public health preparedness.
Read more →EBSEmergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
Emergent BioSolutions celebrates the 10-year anniversary of NARCAN® Nasal Spray's FDA approval, highlighting its impact on opioid overdose treatment. The product has become the first over-the-counter naloxone spray, contributing to a significant decrease in overdose deaths. Despite progress, challenges remain as new drugs continue to emerge, prompting Emergent's ongoing commitment to naloxone access and awareness.
Read more →EBSEmergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
Emergent BioSolutions announced the retirement of Dr. Louis W. Sullivan from its Board of Directors, effective November 14, after 19 years of service. Dr. Sullivan has been a key advisor and leader, contributing to the company's mission and guiding important decisions. His extensive background in healthcare and government has been invaluable during Emergent's transformation.
Read more →EBSCountermeasures Season 3 Episode 3 Podcast Transcript: Biothreats
The podcast discusses the evolving landscape of biological threats, emphasizing the importance of preparedness and collaboration between governments and industries. Experts Wolfgang Philipp and Christopher Frech highlight lessons learned from past crises, such as the COVID-19 pandemic and the 2001 anthrax attacks. They stress the need for strong public-private partnerships and continuous investment in biodefense to ensure readiness for future threats.
Read more →EBSCountermeasures Season 3 Episode 1 Podcast Transcript: Vector-Borne Diseases
The podcast episode discusses the growing threat of vector-borne diseases (VBDs) such as malaria and dengue, exacerbated by climate change and globalization. Experts highlight the importance of education, preventative measures like mosquito nets, and recent vaccine developments in combating these diseases. Despite challenges in access and economic impact, there is optimism for future advancements in public health strategies.
Read more →EBSCountermeasures Season 3 Episode 2 Podcast Transcript: Orthopoxviruses
The podcast discusses the complexities of orthopoxviruses, particularly focusing on smallpox and mpox. It highlights the historical significance of smallpox eradication and the ongoing risks posed by orthopoxviruses due to declining vaccination rates. Experts emphasize the importance of global collaboration, targeted vaccination, and community engagement in addressing these health threats.
Read more →EBS▲ +36.6%on this newsshared move
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
Emergent BioSolutions reported its Q3 2025 financial results, surpassing revenue expectations by $21 million. The company noted strong international demand for its medical countermeasures, despite a decline in revenues from its Naloxone and Anthrax product lines. Overall, Emergent's financial health remains robust, with a focus on long-term growth and shareholder value.
Read more →EBSDocument EMERGENT BIOSO LUTIONS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 million Third Quarter 2025 Net Income of $51.2
Emergent BioSolutions Inc. (NYSE: EBS) reported its financial results for the third quarter of 2025, highlighting total revenues of $231.1 million, which exceeded expectations by $21 million. The company achieved a net income of $51.2 million with a gross margin of 54%. However, the company faced challenges as net income decreased significantly by 55% from the previous year. Despite the drop in income, Emergent remains optimistic, raising its full-year revenue and profitability guidance and citing strong growth in its Naloxone franchise and continuous demand for its medical countermeasures.
Read more →EBSEmergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
Emergent BioSolutions released a survey indicating that 65% of U.S. policy leaders perceive an increasing likelihood of biological attacks, yet 45% feel unprepared. The findings emphasize the need for robust surveillance and partnerships to enhance national security against biological threats. Emergent's experience in developing medical countermeasures positions it as a key player in addressing these challenges.
Read more →EBSEmergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
Emergent BioSolutions Inc. will report its financial results for the third quarter of 2025 on October 29, 2025. A conference call is scheduled for 5:00 PM Eastern Time, where company executives will discuss the results. Participants can access the call via webcast or telephone after registering in advance. A replay will be made available on Emergent's Investors page.
Read more →EBS▲ +5.4%on this news
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
Emergent BioSolutions is reaffirming its commitment to combat the opioid crisis through awareness, education, and increased access to naloxone products. The company highlights its collaboration with various organizations to enhance naloxone availability in workplaces and public settings. Recent awards and initiatives underscore its leadership role in addressing opioid overdose fatalities, which remain a significant public health issue.
Read more →EBSEmergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
Emergent BioSolutions has announced a $29 million purchase order from an international government partner for its medical countermeasures (MCM). This order, which includes products for smallpox, anthrax, and botulism, highlights the increasing global investment in defense preparedness. The company anticipates receiving approximately $26 million in 2025, adding to its substantial sales this year.
Read more →EBSEmergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
Emergent BioSolutions has received a $17 million contract modification from BARDA to supply TEMBEXA oral suspension, following FDA approval for its manufacturing scale-up. This formulation is crucial for patients who struggle with swallowing. The contract emphasizes the need for a reliable supply of smallpox countermeasures, addressing public health security concerns.
Read more →EBS▲ +9.3%on this news
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
Emergent BioSolutions has announced a $56 million contract modification to supply ACAM2000, a vaccine for smallpox and mpox, to the U.S. government. This modification is part of a larger effort to enhance public health preparedness, with total projected sales for the vaccine exceeding $120 million this year. Deliveries are set to begin this month, highlighting the company's commitment to supporting health initiatives.
Read more →EBSEmergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
Emergent BioSolutions has received a $30 million contract modification from BARDA to supply its anthrax vaccine, CYFENDUS. Deliveries are set to begin this year and conclude by March 2026. The vaccine, approved by the FDA in July 2023, is intended for post-exposure prophylaxis against anthrax. This contract follows a previous $50 million modification announced in December 2024.
Read more →EBSEmergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
Emergent BioSolutions is re-launching its 'Ready to Rescue' campaign for International Overdose Awareness Day, focusing on opioid emergency preparedness among college students. The initiative includes events featuring Emmitt Smith and Zac Clark to discuss opioid misuse and mental health. Despite a decline in overdose deaths, challenges persist, particularly in specific states needing enhanced support.
Read more →EBSEmergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™
Emergent BioSolutions is collaborating with Voices for Awareness and Facing Fentanyl Now to promote National Fentanyl Prevention and Awareness Day™ on August 21, 2025. This initiative aims to raise public awareness about the dangers of fentanyl, which significantly contributes to the opioid crisis. High-visibility campaigns in Times Square will highlight the urgent need for education on opioid overdose prevention and the distribution of naloxone. Emergent emphasizes the importance of combating misinformation and equipping the public with life-saving tools to address potential opioid emergencies.
Read more →EBSDocument EMERGENT BIOSO LUTIONS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 million Second Quarter 2025 Net Loss of $12.0 million and Net L
Emergent BioSolutions Inc. reported second quarter 2025 financial results, showcasing total revenues of $140.9 million, which exceeded guidance by $21 million. Despite a net loss of $12.0 million, this figure reflects a significant improvement year-over-year. The company experienced notable growth in adjusted EBITDA, rising by 382%, and improved margins. Emergent also raised its profitability guidance and highlighted successful contract modifications in the biodefense sector.
Read more →EBSEmergent BioSolutions Reports Second Quarter 2025 Financial Results
Emergent BioSolutions reported its financial results for the second quarter of 2025, revealing total revenues of $140.9 million, significantly surpassing initial guidance. The company posted a net loss of $12.0 million, marking an impressive improvement compared to the previous year. Key financial highlights included a 382% increase in adjusted EBITDA. With ongoing contracts and expanding profit margins, Emergent has raised its full-year profitability guidance, demonstrating progress in their multi-year transformation plan despite lower sales in certain product lines.
Read more →EBS▼ -5.4%on this news· ran to -18% by day 3
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
Emergent BioSolutions Inc. has applauded the U.S. House of Representatives for making over-the-counter naloxone available at all AED locations in its buildings. This initiative, spearheaded by Representative Buddy Carter, aims to provide immediate access to lifesaving treatment during opioid overdose emergencies. Emergent emphasizes the importance of naloxone in preventing overdose deaths, citing its significant distribution of NARCAN® Nasal Spray as a pivotal tool in the fight against the opioid crisis. The company continues to advocate for increased awareness and access to overdose reversal treatments.
Read more →EBS▼ -5.1%on this news
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
Emergent BioSolutions Inc. has announced a conference call set for August 6, 2025, to discuss its financial results for the second quarter of 2025. The call will be accessible via webcast and phone for registered participants. Interested investors can find further details on how to join the call on the company's Investors page, highlighting Emergent's dedication to keeping stakeholders informed.
Read more →EBSEmergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
Emergent BioSolutions has announced a contract modification worth $51.9 million to deliver its Vaccinia Immune Globulin Intravenous (Human), CNJ-016, to the U.S. Administration for Strategic Preparedness and Response. This contract is part of an existing agreement aimed at enhancing the nation’s smallpox preparedness. The modification reflects the company's commitment to supporting U.S. public health initiatives and safeguarding against potential threats. Additionally, the article includes important safety information regarding VIGIV treatment and its contraindications.
Read more →EBS▲ +7.7%on this newsshared move
Emergent BioSolutions Expands NARCANDirect to Offer KLOXXADO (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
Emergent BioSolutions has expanded its NARCANDirect distribution network to include KLOXXADO Nasal Spray 8 mg, increasing access to life-saving naloxone for various stakeholders. This move comes after mixed reports on opioid overdose rates, including a recent rise in overdose deaths despite prior declines. The company aims to broaden logistical support and improve emergency response capabilities as part of its commitment to combat the opioid epidemic. Additional offerings, such as Convenience Kits, will also facilitate better preparedness among frontline responders.
Read more →EBSEmergent BioSolutions Secures $62.4 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
Emergent BioSolutions has received a $62.4 million contract modification from the ASPR for the Botulism Antitoxin Heptavalent (BAT), aimed at bolstering the U.S. biodefense supply against potential biological threats. This modification emphasizes the importance of BAT in safeguarding public health following exposure to botulinum neurotoxin. While the funding showcases governmental support, the use of BAT is associated with several risks, including potential severe allergic reactions and limited safety data in vulnerable populations.
Read more →EBSEmergent BioSolutions Announces Addition to Russell 3000 Index
Emergent BioSolutions Inc. has announced its inclusion in the Russell 3000 Index, effective June 27, 2025. This addition marks a critical milestone for the company as it transitions towards promoting sustained growth and financial stability. The Russell 3000 Index is widely regarded by investors and includes the largest U.S. stocks by market capitalization. The CEO, Joe Papa, expressed optimism about the company's future direction following this recognition.
Read more →EBSEmergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
Emergent BioSolutions is partnering with Victoria's Voice Foundation to promote National Naloxone Awareness Day on June 6. This initiative aims to combat the opioid crisis by increasing access to naloxone and educating the public on its use. The campaign includes the distribution of NARCAN® Nasal Spray and promotes participation in the '#sharenaloxone' social media initiative. Recent CDC reports indicate a noteworthy decline in opioid-related deaths, underlining the importance of such preventative measures in saving lives.
Read more →EBSDocument EX-99.1 UNITED STATES DISTRICT COURT DISTRICT OF MARYLAND IN RE EMERGENT BIOSOLUTIONS INC., STOCKHOLDER DERIVATIVE LITIGATION Master Case No. 8 21-cv-01595-DLB (Consolidated with No. 8 21-cv-02079-DLB) This Docu
Emergent BioSolutions is involved in ongoing stockholder derivative litigation, asserting that individual defendants failed in their fiduciary duties by not ensuring compliance at their manufacturing facility. Allegations include poor oversight leading to contamination incidents, which prompted the FDA to cease vaccine production. As a result, the company has suffered substantial financial losses and ongoing litigation challenges, including securities fraud claims. The legal actions consolidate multiple cases against the company and its directors regarding these issues.
Read more →EBSEmergent BioSolutions Reports First Quarter 2025 Financial Results
Emergent BioSolutions reported its financial results for the first quarter of 2025, revealing a 26% decline in total revenues compared to the previous year, totaling $222.2 million. However, net income saw a remarkable 656% increase, amounting to $68 million. The company maintained steady financial guidance for the year, citing improvements in profitability margins and overall cash flow. Despite strong performance in adjusted earnings metrics, the significant drop in sales for products like NARCAN highlights ongoing challenges in certain segments.
Read more →EBSDocument EMERGENT BIOSO LUTIONS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior year First Quarter 2025 Net Income of $68.0 million, increase
Emergent BioSolutions has reported its financial results for the first quarter of 2025, indicating a total revenue of $222.2 million, down 26% from the previous year. However, net income has seen a remarkable increase to $68 million, a 656% rise year-over-year. The company attributes its positive income results to operational improvements and increased profitability margins. Despite the solid net income, the drop in total revenues and significant decreases in specific product sales could signal challenges in the company's revenue streams.
Read more →EBS▼ -7.9%on this news
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
Emergent BioSolutions has announced a three-year agreement with the Ontario Ministry of Health valued at approximately $65 million to supply NARCAN® Nasal Spray for the Ontario Naloxone Program. This agreement aids in increasing access to life-saving intervention for opioid poisoning, addressing a serious public health issue in the region. The partnership aims to distribute the nasal spray across various community organizations and to individuals at risk of overdose. Recently, a 30% decrease in overdose deaths was reported, highlighting the ongoing need for effective opioid emergency responses.
Read more →EBSEmergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
Emergent BioSolutions Inc. has announced a conference call scheduled for May 7, 2025, at 5:00 PM Eastern Time, where the company will discuss its financial results for the first quarter of 2025. Participants can access the call through a webcast or telephone after registering in advance. This event will allow investors to gain insights into the company's performance, although further details on the financial results themselves are yet to be disclosed.
Read more →EBSEmergent BioSolutions Announces Stock Repurchase Program
Emergent BioSolutions has announced a stock repurchase program authorizing the buyback of up to $50 million of its common stock, which is expected to conclude by March 27, 2026. This initiative aligns with the company’s multi-year transformation plan aimed at enhancing growth and profitability. The timing and amount of shares repurchased will depend on market conditions and other factors. The announcement underscores the company's confidence in its strategy and cash generation capabilities.
Read more →EBSEmergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
Emergent BioSolutions Inc. announced the granting of an equity award to a newly hired employee under its 2023 Inducement Plan. The award consists of restricted stock units and stock options totaling 72,882 shares of common stock, which will vest fully on March 15, 2026, contingent on the employee's continuous service. This decision reflects the company's strategy to attract and retain talented individuals in the public health sector.
Read more →EBSEmergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Emergent BioSolutions Inc. has completed the sale of its Baltimore-Bayview manufacturing site to Syngene International for approximately $36.5 million. This sale enables Emergent to streamline its operations while retaining rights for future manufacturing services at the facility. The CEO highlighted that this step is part of a broader transformation aimed at achieving sustainable long-term growth. Truist acted as the financial advisor for the transaction, with legal counsel provided by Covington & Burling LLP.
Read more →EBSEmergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
Emergent BioSolutions announced it has secured approximately $27 million in international orders for its medical countermeasure portfolio, aimed at addressing potential threats such as smallpox and anthrax. These orders are set for delivery in 2025 and will support the global supply of essential medical products. CEO Joe Papa highlighted the company’s commitment to enhancing public health preparedness both domestically and internationally through its multi-year transformation plan.
Read more →EBS▼ -10.4%on this newsshared move
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
Emergent BioSolutions Inc. is enhancing its efforts to combat the opioid crisis by supporting various organizations in expanding access to NARCAN Nasal Spray. This initiative includes collaborations with the NYC Building & Construction Industry Safety Fund to provide training and opioid emergency kits to construction workers. Additionally, Emergent is working with Pathway Healthcare to ensure that NARCAN is available at its Mississippi locations, thereby reducing barriers to access for individuals at risk. These efforts coincide with a recent decline in opioid overdose deaths in the U.S., highlighting the positive impact of increased education and availability of rescue medications.
Read more →EBS▲ +11.2%on this newsshared move
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
Emergent BioSolutions has entered into a strategic investment agreement with Rocketvax, a Swiss biotech company, to support the development of innovative vaccine candidates. This partnership will focus on U.S. manufacturing and commercialization, including a collaboration with the NIH for a new vaccine trial. Emergent's investment is aimed at enhancing the biotechnology portfolio of Rocketvax and advancing public health technologies, particularly in response to infectious diseases and cancer. Both companies express optimism about the potential impact of their combined efforts on global health.
Read more →EBSEmergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Emergent BioSolutions Inc. has announced the sale of its Baltimore-Bayview manufacturing facility to Syngene International for $36.5 million. This agreement allows Emergent to retain manufacturing services at the site for future needs while continuing its multi-year transformation plan. The sale is expected to close in the first quarter of 2025, subject to customary conditions. Emergent's CEO highlighted the potential for growth in its core products, underscoring their commitment to delivering high-quality healthcare solutions.
Read more →EBS▼ -8.7%on this news· ran to -22% by day 3
Document EMERGENT BIOSO LUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Fourth Quarter 2024 Total Revenues of $194.7 million Full Year 2024 Total Revenues of $1.04 billion Fourth Quarter 2024 Net Loss
Emergent BioSolutions Inc. reported its financial results for Q4 and the full year of 2024, showing total revenues of $194.7 million for the fourth quarter and $1.04 billion for the year. Despite a net loss of $31.3 million for Q4, the company noted a decrease in losses by 37% from the prior year. Significant positive indicators include a 518% increase in adjusted EBITDA year-over-year and favorable guidance for 2025 with expectations of strong adjusted EBITDA. However, there were substantial declines in revenue from key products like NARCAN and Anthrax MCM, reflecting potential vulnerabilities in these areas.
Read more →EBS▼ -8.7%on this news· ran to -22% by day 3
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
Emergent BioSolutions reported its financial results for the fourth quarter and full year of 2024, indicating total revenues of $194.7 million for Q4 and $1.04 billion for the entire year. Despite an overall revenue decline of 30% in Q4, the company achieved a substantial increase in Adjusted EBITDA, rising by 518% compared to the same quarter last year. Looking forward, Emergent provided positive guidance for 2025, projecting an Adjusted EBITDA of $150 to $200 million. The results reflect the strategic efforts to stabilize the business while adapting to market conditions.
Read more →EBS▼ -14.2%on this news
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Emergent BioSolutions Inc. is set to announce its fourth quarter and full year financial results for 2024 on March 3, 2025. The company will conduct a conference call at 5:00 pm Eastern Time to discuss these results. Interested participants can access the call via webcast or telephone by registering in advance. Additionally, Emergent is participating in the J.P. Morgan 2025 Leveraged Finance Conference with a presentation scheduled for February 24, 2025.
Read more →EBSEmergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
Emergent BioSolutions has teamed up with Emmitt Smith to promote the Ready to Rescue campaign in New Orleans ahead of a major sporting event. The initiative aims to educate the public on opioid overdose preparedness, featuring a video and local distribution of NARCAN Nasal Spray. Although recent statistics show a decline in national opioid overdose deaths, areas like New Orleans continue to see rising numbers in drug-related fatalities. The campaign is designed to inform and empower citizens to combat opioid emergencies effectively.
Read more →EBSThis presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding t
Emergent BioSolutions provided a presentation highlighting forward-looking statements related to its future business performance and strategic initiatives. They identified several potential risks that could impact earnings, including reliance on government procurement contracts for medical countermeasures. Additionally, the company acknowledged challenges such as competition in the market for their NARCAN product, as well as uncertainties regarding contract negotiations and compliance with regulatory standards. These factors contribute to caution in projecting future financial outcomes.
Read more →EBSEmergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
Emergent BioSolutions has secured exclusive commercial rights in the U.S. and Canada for Hikma Pharmaceuticals' KLOXXADO, an 8 mg naloxone nasal spray. This six-year partnership aims to enhance the availability of life-saving treatments for opioid overdoses, complementing Emergent's existing NARCAN nasal spray. The agreement aligns with a broader strategy to combat the opioid crisis, as recent data indicates a reduction in opioid overdose deaths in the U.S. Emergent's commitment includes increasing access and awareness of naloxone products across various communities.
Read more →EBSEmergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
Emergent BioSolutions has announced a $16.7 million contract option from the Biomedical Advanced Research and Development Authority (BARDA) to continue the development of Ebanga™ (ansuvimab-zykl) for treating Zaire Ebola virus infections. This funding is part of a larger 10-year agreement with BARDA, worth up to $704 million, aimed at advancing the drug's manufacturing and stability testing. The developments aim to enhance preparedness against Ebola, which remains a significant public health concern.
Read more →EBSEmergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax (Anthrax Vaccine Adsorbed)
Emergent BioSolutions Inc. has exercised a $20 million option under its existing contract with the U.S. Department of Defense to supply BioThrax (Anthrax Vaccine Adsorbed). The deal ensures the continued delivery of this vital vaccine to protect military personnel at risk of anthrax exposure. The first portion of the contract was valued at $7 million, with additional deliveries planned for 2025. This contract highlights Emergent's role in public health preparedness against biothreats.
Read more →EBSEmergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Emergent BioSolutions, a public health-focused company, has announced that its CEO, Joe C. Papa, will present at the J.P. Morgan Healthcare Conference on January 15, 2025. This occasion provides the company an opportunity to highlight its protective and life-saving solutions. The presentation will be available live and for later access via their website, reflecting their transparency and commitment to stakeholders.
Read more →EBSEmergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions has been awarded a $50 million contract option by the Biomedical Advanced Research and Development Authority (BARDA) to procure doses of the CYFENDUS anthrax vaccine. This follows a previous $30 million contract modification for the same vaccine. The CYFENDUS vaccine was approved by the FDA in July 2023 for post-exposure prophylaxis in individuals aged 18 to 65. Deliveries are scheduled to begin this year and conclude by April 2025, reflecting a commitment to bolster public health preparedness against bioterrorism threats.
Read more →EBSDocument EMERGENT BIOSO LUTIONS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Third Quarter 2024 Total Revenues of $293.8 million, increase of 9% versus prior year Third Quarter 2024 Net Income of $114.8 million, increase
Emergent BioSolutions reported its financial results for the third quarter of 2024, highlighting a 9% increase in total revenues to $293.8 million, alongside a remarkable 144% rise in net income to $114.8 million. Adjusted EBITDA surged by 432% to $105.3 million. The company is focusing on profitable growth as it enters a turnaround phase, driven by improvements in customer demand and operational efficiencies. However, sales for specific products, such as NARCAN and Anthrax MCM, saw significant declines, underscoring ongoing market challenges.
Read more →EBSEmergent BioSolutions Reports Third Quarter 2024 Financial Results
Emergent BioSolutions reported strong financial results for Q3 2024, with total revenues of $293.8 million reflecting a 9% increase from the previous year. Notably, net income rose by 144%, and adjusted EBITDA soared by 432%, demonstrating significant operational improvements. The company raised its FY 2024 guidance, indicating confidence in ongoing progress and profitability. However, some challenges remain, including declines in specific product revenues that highlight market variability.
Read more →EBSEmergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
Emergent BioSolutions announced its support for a clinical trial evaluating brincidofovir in treating the mpox virus across Africa. The study, known as the MpOx Study in Africa (MOSA), will be led by the Africa Centres for Disease Control and Prevention and aims to assess the safety and efficacy of the antiviral drug. Currently, there are no FDA-approved therapies for patients with severe mpox infections, highlighting the importance of this trial in addressing the public health emergency declared by the Africa CDC and WHO.
Read more →EBSEmergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
Emergent BioSolutions has announced the appointment of Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development, effective November 18. Dr. Lowry brings over 25 years of experience in the healthcare and pharmaceutical industries and is expected to lead the company’s scientific roadmap. Alongside, Jessica Perl has been promoted to General Counsel and Corporate Secretary, signaling internal advancement within the company. This leadership transition is part of Emergent's broader transformation strategy.
Read more →EBS▼ -5.2%on this news
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
Emergent BioSolutions Inc. plans to host a conference call on November 6, 2024, to discuss its financial results for the third quarter of 2024. During the call, the company will cover recent business developments and provide a financial outlook for the full year 2024. Participants can join the call via webcast or telephone. Details for accessing the call and a replay will be available on the company's Investors page.
Read more →EBSCountermeasures Season 2 Episode 6 Podcast Transcript: Aging During the Opioid Crisis
The podcast discusses the impact of the opioid crisis on older adults, highlighting that stereotypes often prevent recognition of substance misuse in this demographic. Experts emphasize the rising rates of opioid overdoses among seniors and the need for tailored treatment and harm reduction services. The conversation also addresses the stigma that hinders older adults from seeking help.
Read more →EBSCountermeasures Season 2 Episode 5 Podcast Transcript: Preparing Students for Opioid Emergencies
The podcast episode discusses harm reduction efforts aimed at college students, highlighting the importance of peer-to-peer education in addressing opioid emergencies. It features insights from student leaders involved in the Carolina Harm Reduction Union, who emphasize the need for open conversations about substance use. The episode also addresses the risks associated with accidental overdoses and the ongoing stigma surrounding addiction.
Read more →EBSEmergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN Nasal Spray to Help Combat the Opioid Epidemic
Emergent BioSolutions is enhancing access and awareness of NARCAN Nasal Spray to combat opioid overdoses. Marking the one-year anniversary of its Ready to Rescue campaign, the company has donated 20,000 doses of the nasal spray and provided education on opioid overdose response. Additionally, evidence suggests a decline in opioid overdose deaths in the U.S., emphasizing the importance of such initiatives. Through collaborations with organizations like the National Safety Council, Emergent aims to further expand public access and education regarding life-saving treatments.
Read more →EBS▲ +8.5%on this news
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility GAITHERSBURG, Md.
Emergent BioSolutions Inc. has announced the closing of a $100 million asset-based revolving loan facility, with Wells Fargo Bank as the administrative agent. This credit agreement is part of Emergent's multi-year transformation plan and has a maturity date of September 30, 2029. The company reported a cash balance of approximately $150 million and indicates that this facility will provide additional liquidity for its strategic goals. This move follows a recent announcement of refinancing efforts, enhancing Emergent's overall financial strength.
Read more →EBSCountermeasures Season 2 Episode 4 Podcast Transcript: Creating Safer Workplaces
The podcast discusses the opioid crisis's impact on workplace safety, highlighting the importance of naloxone training and availability. Lorraine Martin from the National Safety Council emphasizes the need for a strong safety culture that includes addressing substance use disorders. The episode features insights from various experts advocating for recovery-friendly workplaces and the role of government initiatives in promoting naloxone use.
Read more →EBS▲ +22.6%on this news· ran to +43% by day 3shared move
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA (brincidofovir) to Support National Preparedness Efforts
Emergent BioSolutions has successfully executed contract options worth $67.4 million to procure additional doses of TEMBEXA (brincidofovir), aimed at bolstering the U.S. government's preparedness for smallpox. This procurement is a part of an existing 10-year contract and ensures a continuous supply of the antiviral, which has been FDA-approved since June 2021. The funding will support smallpox preparedness efforts until 2027 and showcases the robust partnership between Emergent and the U.S. government in public health initiatives.
Read more →EBSEmergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
Emergent BioSolutions Inc. announced the acquisition of approximately $400 million in orders for their smallpox and mpox product portfolio for 2024 and 2025. This includes U.S. government contracts for ACAM2000 and Vaccinia Immune Globulin Intravenous. Notably, the FDA recently approved an update for ACAM2000 to include mpox prevention, and Emergent has initiated the process for Emergency Use Listing with the WHO. Additionally, the company has pledged 50,000 doses of ACAM2000 to support efforts in countries affected by mpox.
Read more →EBSEmergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
Emergent BioSolutions has announced a $40 million agreement to settle a securities class action lawsuit that has been pending since 2021. The settlement, which covers stock purchases made between March 10, 2020, and November 4, 2021, will be funded largely through insurance proceeds. Importantly, the agreement contains no admission of liability from Emergent or any current or former company officials. The company views this settlement as a major step towards moving past the litigation and refocusing on its business objectives.
Read more →EBSCountermeasures Season 2 Episode 3 Podcast Transcript: Keeping Students Safe From Opioid Overdose
The podcast discusses the ongoing opioid crisis, focusing on student advocacy for naloxone access in schools. Students like Hays Stritikus have taken initiative to educate peers and push for legislation allowing naloxone on campuses. The episode highlights the importance of youth involvement in addressing the crisis and the need for comprehensive drug education.
Read more →EBSEmergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
Emergent BioSolutions has been awarded a $41.9 million contract modification by BARDA to further develop and procure the Ebanga treatment for Ebola virus disease. This funding will facilitate drug substance engineering, scale-up process validation, and stability studies as part of the company's ongoing scale-up program. The contract's execution reflects Emergent's commitment to advancing its capabilities in providing critical medical countermeasures against Ebola.
Read more →EBSCountermeasures Season 2 Episode 2 Podcast Transcript: Compassionate Care for New Mothers
The podcast discusses the challenges faced by mothers struggling with opioid dependency and the support provided by organizations like Hushabye Nursery and Heart Rock Justus Family Recovery Center. These facilities offer compassionate, trauma-informed care that helps mothers and their babies during recovery. They emphasize the importance of peer support and education to empower families and reduce stigma associated with substance use.
Read more →EBS▼ -11.1%on this newsshared move
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround
Emergent BioSolutions Inc. has announced a new credit facility agreement with Oak Hill Advisors, securing a term loan of up to $250 million, which will refinance existing debt and enhance cash reserves. This strategic refinancing extends the maturity of the loan to August 2029 and is part of the company's multi-year plan to stabilize and improve its financial profile. Management anticipates a reduction in net debt exceeding $200 million this year, positioning the company for future growth and investment opportunities. The deal includes the issuance of warrants and shares to lenders, reflecting confidence in the company's turnaround strategy.
Read more →EBS▼ -6.7%on this newsshared move
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
Emergent BioSolutions has launched the second year of its Ready to Rescue initiative aimed at promoting opioid emergency preparedness, with a focus on educating college communities about the use of NARCAN® Nasal Spray. The campaign includes events at major universities and seeks to reduce stigma around opioid use. The CDC recently reported a reduction in overdose deaths, but opioid poisonings remain a major issue, especially among young adults. The initiative aims to equip individuals with knowledge and tools to save lives, emphasizing the importance of community awareness in combating the opioid crisis.
Read more →EBSEmergent BioSolutions’ ACAM2000 , (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
Emergent BioSolutions has received FDA approval to expand the indication of ACAM2000 to include mpox prevention for high-risk individuals. This decision is timely as a public health emergency declares the mpox outbreak, particularly in Africa, requiring immediate action. The company plans to donate 50,000 doses to support the global response. Despite the positive approval, the rising cases of mpox and associated risks for those receiving the vaccine highlight ongoing public health challenges.
Read more →EBS▲ +8.8%on this news
Countermeasures Season 2 Episode 1 Podcast Transcript: Improving Outcomes in Jails and Prisons
The podcast episode discusses the challenges faced by incarcerated individuals struggling with opioid use disorders and the efforts being made to improve their outcomes. It highlights the importance of Medication Assisted Treatment (MAT) programs in jails, the role of peer support, and the need for better resources and support systems upon release. Success stories illustrate the potential for recovery, but significant barriers remain, including inconsistent treatment access and high overdose risks after release.
Read more →EBS▼ -20.3%on this newsshared move
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
Emergent BioSolutions has completed the sale of its drug product facility located in Baltimore-Camden to Bora Pharmaceuticals for around $30 million. This sale is intended to support Emergent's multi-year plan to stabilize and transform the company, particularly focusing on improving profitability and reducing debt. Bora Pharmaceuticals has acquired not only the facility but also the associated assets and workforce. Emergent's CEO emphasized this milestone as a crucial step in their strategic efforts.
Read more →EBS▲ +12.7%on this newsshared move
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
Emergent BioSolutions announced its proactive measures in response to the mpox outbreak in Central Africa, collaborating with the World Health Organization and the U.S. government. The company has pledged to donate 50,000 doses of its ACAM2000 vaccine to assist in controlling the outbreak. Additionally, Emergent has submitted a supplemental Biologics License Application to expand the use of ACAM2000 to include immunization against mpox virus. The World Health Organization declared the mpox surge in Africa a public health emergency of international concern.
Read more →EBSEmergent BioSolutions Reports Second Quarter 2024 Financial Results
Emergent BioSolutions reported its financial results for Q2 2024, showing total revenues of $254.7 million, which surpassed prior expectations. However, the company experienced a net loss of $283.1 million, marking an 8% increase from the previous year's loss. Despite this, Emergent has made progress in debt reduction and anticipates exceeding $200 million by year-end. The company also announced strategic asset divestitures and a notable increase in Bioservices revenues.
Read more →EBSEmergent BioSolutions Expands NARCAN Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
Emergent BioSolutions Inc. has launched a new NARCANDirect distribution center in Nevada to enhance nationwide access to its NARCAN Nasal Spray. This initiative aims to improve delivery capabilities for emergency medical services and other public interest organizations, ensuring faster and more efficient distribution. Since its introduction in 2016, the company has distributed approximately 64 million doses, underscoring its commitment to addressing the opioid epidemic in the U.S. and Canada. The expansion reflects a strategic response to growing demand for naloxone as a critical tool in emergency overdose situations.
Read more →EBSDocument EMERGENT BIOSO LUTIONS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance range Second Quarter 2024 Net Loss of $283.1 million and Adjust
Emergent BioSolutions Inc. reported its financial results for the second quarter of 2024, revealing total revenues of $254.7 million, which surpassed their prior guidance. However, the company experienced a net loss of $283.1 million, a noticeable increase compared to the same period last year. Despite the losses, Emergent indicated plans for a significant debt reduction of over $200 million by year-end. Additionally, the company secured a $250 million contract modification with the U.S. government and announced the sale of certain assets to streamline operations.
Read more →EBS▲ +7.1%on this news· ran to -18% by day 3
Emergent BioSolutions Completes Sale of RSDL (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
Emergent BioSolutions Inc. has completed the sale of its RSDL (Reactive Skin Decontamination Lotion) kit to SERB Pharmaceuticals for approximately $75 million. As part of the deal, SERB will also take over operations of Emergent's Hattiesburg manufacturing facility and assume certain contracts. This sale is part of Emergent’s strategy to reduce its debt by over $150 million through operational performance improvements and asset divestments, indicating a focus on stabilizing the company's financial health.
Read more →EBS▲ +10.6%on this news
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
Emergent BioSolutions has launched the 'Lay, Spray, Stay' public education campaign to raise awareness about responding to potential opioid overdoses. The campaign features NFL Hall of Famer Emmitt Smith and aims to educate the public on the use of NARCAN® Nasal Spray as a life-saving tool. With over 100,000 drug overdose deaths in 2023 primarily due to opioids, this initiative seeks to break the stigma associated with opioid emergencies and enable individuals to assist in life-saving situations. The effort is part of Emergent's broader Ready to Rescue initiative, developed in partnership with SAFE Project.
Read more →EBS▲ +9%on this news· ran to +22% by day 3shared move
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
Emergent BioSolutions Inc. will hold a conference call on August 6, 2024, to discuss its financial results for the second quarter of 2024. The call will include key business updates and revenue guidance for the third quarter and full year. Participants can access the call via webcast or telephone with prior registration. A replay of the call will be available on the company’s Investors page.
Read more →EBSEmergent BioSolutions Announces Shelf-Life Extension for NARCAN Nasal Spray in Canada
Emergent BioSolutions has announced a shelf-life extension for its NARCAN® Nasal Spray in Canada, increasing it from three years to four years for newly manufactured products. This extension helps improve access to naloxone, a critical medication for reversing opioid overdoses, amidst rising opioid-related hospitalizations in the country. NARCAN® is now the only 4 mg, intranasal naloxone spray in Canada with this longer shelf life. The company distributed around 22 million doses in 2023 and continues to support public awareness initiatives to combat the opioid crisis.
Read more →EBS▲ +7.3%on this news· ran to +31% by day 3
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
Emergent BioSolutions Inc. has made significant strides in enhancing its financial health as part of a multi-year transformation plan. The company reported robust cash generation and meaningful debt repayments, including securing $250 million in U.S. government contracts and selling its Baltimore-Camden manufacturing site for $30 million. The resolution of a contract dispute with Janssen Pharmaceuticals also provides a $50 million boost to its finances. Emergent aims for over $100 million in debt reduction this year while continuing to support public health initiatives.
Read more →EBS▲ +6.1%on this news
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
Emergent BioSolutions has been awarded more than $250 million in contract modifications by the U.S. Department of Health and Human Services to supply four critical medical countermeasures. These include vaccines and treatments for anthrax, smallpox, and botulism, aimed at bolstering national preparedness against biological threats. The funding supports existing contracts and underscores Emergent's role as a trusted partner in biodefense. These contracts encompass significant contributions to the Strategic National Stockpile, ensuring readiness for public health emergencies.
Read more →EBS▲ +6.8%on this news
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
Emergent BioSolutions has announced the sale of its Baltimore-Camden manufacturing site to Bora Pharmaceuticals for approximately $30 million. This move is part of Emergent's strategic efforts to streamline operations and improve profitability. The transaction is expected to close in the third quarter of 2024 and will transfer 350 employees to Bora. By divesting this facility, Emergent aims to enhance its focus on core areas for future growth.
Read more →EBS▼ -6.1%on this news
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
Emergent BioSolutions is commemorating National Naloxone Awareness Day by highlighting its efforts to address the opioid epidemic in the U.S. The company shared results from a recent survey indicating high awareness of naloxone's ability to reverse opioid overdoses but noted significant gaps in understanding, particularly among younger and less educated populations. Emergent continues to expand access to its NARCAN® Nasal Spray, an FDA-approved OTC naloxone product, while collaborating with the White House to enhance public education and accessibility efforts. Despite some positive trends, the ongoing rise in fentanyl-related deaths remains a pressing concern.
Read more →EBSEmergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
Emergent BioSolutions Inc. announced that its 2024 Annual Meeting of Stockholders will take place virtually on May 23, 2024, at 9:00 AM ET. Eligible stockholders can participate and ask questions via a live audio webcast by logging in with a Control Number. Those without a Control Number may listen in but will not have voting rights. The company highlights the importance of early login for participants and will provide a replay of the event on its website.
Read more →EBSDocument EMERGENT BIOSO LUTIONS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance range First Quarter 2024 Net Income of $9.0 million and Adjusted
Emergent BioSolutions Inc. reported strong financial results for the first quarter of 2024, with total revenues reaching $300.4 million, significantly exceeding prior guidance. The company experienced a net income of $9.0 million, transitioning from a substantial loss in the same quarter last year. Key growth drivers included increased sales in its NARCAN and Anthrax product lines. However, the company faced challenges, including zero sales in other commercial products and a notable drop in bioservices revenue from leases.
Read more →EBSEmergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
Emergent BioSolutions Inc. released findings from a national survey indicating strong public awareness regarding opioid overdoses, particularly among teenagers and college students. Over 90% of respondents support increased education and access to NARCAN® Nasal Spray to address this crisis. The survey highlights a disconnect between public perception and the reality of overdose deaths, as many respondents significantly underestimated the annual death toll. Emergent continues its efforts to combat the opioid epidemic with a national campaign aimed at raising awareness and destigmatizing naloxone use.
Read more →EBSEmergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
Emergent BioSolutions announced a strategic reorganization aimed at stabilizing its financial position and ensuring long-term sustainability. This operational change involves consolidating operations, closing two manufacturing facilities, and reducing its workforce by approximately 300 employees. The company projects annual cost savings of around $80 million, despite incurring restructuring costs estimated between $18 million and $21 million. To adapt to the changing business landscape, a new Chief Science Officer role has also been established within the executive team.
Read more →EBSEmergent BioSolutions Reports First Quarter 2024 Financial Results
Emergent BioSolutions Inc. reported strong financial results for the first quarter of 2024, with total revenues of $300.4 million, an 83% increase year-over-year. The company achieved a net income of $9 million, compared to a significant loss in the previous year. Alongside this financial growth, Emergent announced it was awarded a substantial contract to supply BioThrax to the U.S. Department of Defense. Despite these positives, the company faced challenges, including zero sales in certain commercial product segments and a substantial decline in lease revenues from its Bioservices business.
Read more →EBSEmergent BioSolutions Announces Amendment to its Existing Credit Facility
Emergent BioSolutions Inc. announced a significant amendment to its existing credit facility, providing the company with an extended runway to stabilize its financial position. CEO Joe Papa emphasized the constructive collaboration with their banking partners, indicating a positive step forward for the company's business plan. Emergent will also report its Q1 2024 financial results and provide guidance for the upcoming quarters, showcasing an active engagement with its financial stakeholders.
Read more →EBS▲ +5.9%on this news
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
Emergent BioSolutions Inc. has announced a conference call scheduled for May 1, 2024, to discuss its financial results for the first quarter of 2024. During the call, the company will also provide updates about its business and revenue guidance for the upcoming second quarter and the full year. Participants can join the call via a webcast or by telephone after registering. A replay will be available on the company's Investors page following the event.
Read more →EBSEmergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
Emergent BioSolutions is actively working to broaden access to its NARCAN Nasal Spray, following its historic over-the-counter approval by the FDA. Their efforts have led to distribution in over 32,000 retail locations and approximately 22 million doses distributed in 2023. Emergent remains committed to increasing awareness and reducing stigma associated with naloxone use, partnering with various organizations to reach more people. However, the ongoing opioid crisis, resulting in a significant number of overdose deaths, underscores the need for expanded access and education regarding the medication's use in emergencies.
Read more →EBS▲ +5.4%on this newsshared move
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
Emergent BioSolutions announced that its Baltimore Bayview manufacturing facility has received 'No Action Indicated' (NAI) status from the FDA, indicating compliance with current good manufacturing practices. This achievement reflects the company’s ongoing commitment to quality and compliance in its operations. Company executives expressed pride in the efforts of their teams to secure this status following a series of successful inspections by regulatory bodies. Emergent aims to maintain high-quality manufacturing standards in serving its customers and patients.
Read more →EBSDocument EMERGENT BIOSO LUTIONS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidance Full Year 2023 Total Revenues of
Emergent BioSolutions (NYSE: EBS) reported its fourth quarter 2023 financial results, revealing total revenues of $277 million, which aligns with its annual guidance. The company experienced a net loss of $50 million, although this was an improvement from the previous year's loss. Notable developments include FDA approval for the anthrax vaccine CYFENDUS and the launch of OTC NARCAN, aimed at broadening customer access. Despite these advancements, the overall revenue decreased by 16% from the prior year, indicating underlying financial challenges.
Read more →EBSEmergent BioSolutions Reports Fourth Quarter 2023 Financial Results
Emergent BioSolutions reported its financial results for the fourth quarter of 2023, highlighting a total revenue of $277 million, a 16% decline from the previous year. The company faced a net loss of $50 million during the quarter, although it achieved an adjusted EBITDA of $3 million. Key developments include the FDA approval of the anthrax vaccine CYFENDUS® and the launch of the over-the-counter NARCAN® nasal spray, aimed at broadening sales. Despite positive developments, the company continues to navigate significant financial challenges and a reshaping of its product portfolio.
Read more →EBSEmergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
Emergent BioSolutions Inc. will conduct a conference call on March 6, 2024, to discuss its financial results for the fourth quarter and full year of 2023. Newly appointed president and CEO Joseph C. Papa is set to provide remarks during the call. Investors can access the meeting live through a webcast or via telephone, with necessary registration details provided. A replay of the call will be available on the company's website after the event.
Read more →EBS▲ +78.3%on this news
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
Emergent BioSolutions has appointed Joseph C. Papa as its new president and CEO, effective February 21, 2024. Papa succeeds Haywood Miller, who served as interim CEO. His experience in the pharmaceutical and healthcare industry is expected to drive growth and improve the company's financial position. Under his leadership, Emergent aims to focus on public health, enhance product delivery, and pay down debt while continuing to respond to global health challenges.
Read more →EBS▼ -5.4%on this news
Countermeasures Season 1 Bonus Episode Podcast Transcript: The Role of Government in Combating the Opioid Crisis
In the final episode of the Countermeasures podcast, Congressman Dave Joyce discusses the ongoing opioid crisis in Ohio, highlighting the impact of fentanyl. He emphasizes the need for legislative action to equip communities and first responders to combat addiction. Jessica Hulsey from the Addiction Policy Forum shares insights on addressing stigma and improving resources for those affected by substance use disorders. Together, they advocate for a comprehensive approach to tackling this public health crisis.
Read more →EBSEmergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
Emergent BioSolutions Inc. has been awarded a significant indefinite-delivery, indefinite-quantity procurement contract with the U.S. Department of Defense, valued at up to $235.8 million. This contract includes a five-year base agreement for supplying BioThrax, an anthrax vaccine, as pre-exposure prophylaxis for military personnel. Under the agreement, there is a guaranteed purchase minimum of $20.1 million, with future orders expected to reach at least $20 million annually. This contract underscores the strategic role of Emergent's vaccine portfolio in national defense against biological threats.
Read more →EBSEmergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
Emergent BioSolutions, a global leader in public health solutions, has announced that its Interim CEO and CFO will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The presentation will include a live audio link and slides available on the company's investor section post-event. This participation reflects the company's commitment to public health and investor engagement.
Read more →EBSCountermeasures Season 1 Episode 6 Podcast Transcript: How Tribal communities are addressing the opioid crisis
The podcast episode discusses the severe impact of the opioid crisis on Native American communities, particularly focusing on the role of historical trauma and the introduction of fentanyl. It features personal narratives from individuals affected by addiction and highlights community-led initiatives aimed at recovery through cultural reconnection. The episode emphasizes the need for culturally centered treatment to effectively combat the crisis.
Read more →EBSCountermeasures Season 1 Episode 5 Podcast Transcript: On the Front Lines of the Opioid Crisis
The podcast episode discusses the opioid crisis and its impact on first responders. It highlights the increasing number of overdose calls and the need for better training and mental health support for EMS personnel. Positive initiatives like Safe Stations and peer mentorship programs are emerging to aid recovery and support responders. The episode emphasizes the importance of community partnerships in addressing the crisis.
Read more →EBSCountermeasures Season 1 Episode 4 Podcast Transcript: Caring for Children of the Opioid Epidemic
The podcast episode discusses Camp Mariposa, a program designed to support children impacted by the opioid epidemic. It features personal stories from participants who found community and mentorship through the camp. The program aims to mitigate the effects of adverse childhood experiences by fostering positive relationships and life skills. Evidence suggests that Camp Mariposa significantly reduces the likelihood of substance use among its attendees.
Read more →EBSEmergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions has received a $75 million contract option from BARDA for the procurement of CYFENDUS™, an anthrax vaccine approved by the FDA in July 2023. The contract is part of ongoing efforts to enhance national biodefense against anthrax and is set to support the acquisition of doses expected by early 2024. CYFENDUS™ is essential for post-exposure prophylaxis in adults, addressing a critical public health threat associated with anthrax exposure.
Read more →EBSEmergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
Emergent BioSolutions Inc. confirmed it received a non-compliance notice from the NYSE regarding a delay in filing its Quarterly Report on Form 10-Q for the quarter ending September 30, 2023. The company is working to address issues related to state deferred tax liabilities and income tax benefits, which have hindered its ability to finalize financial statements. Emergent has a six-month window to become compliant again with NYSE standards after filing the necessary reports.
Read more →EBS▼ -6.4%on this news· ran to -23% by day 3
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
Emergent BioSolutions reported its third quarter 2023 financial results, revealing total revenues of $271 million, which exceeded previous guidance. Despite achieving these revenues, the company faced a pre-tax loss of $266 million during the same period. The company also announced the FDA approval of an anthrax vaccine and the over-the-counter launch of NARCAN® Nasal Spray, aiming to enhance availability and impacts of their products. Furthermore, the company indicated that it needs to postpone the filing of its full quarterly report due to corrections in prior financial statements.
Read more →EBS▼ -6.4%on this news· ran to -23% by day 3
Document EMERGENT BIOSO LUTIONS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS Third Quarter 2023 Total Revenues of $271M, above the prior guidance range Third Quarter 2023 Pre-Tax Loss of $(266)M and Adjusted EBITDA (2) o
Emergent BioSolutions reported its third quarter 2023 financial results, revealing total revenues of $271 million, surpassing previous guidance. However, the company also faced a pre-tax loss of $266 million and indicated the necessity to adjust prior financial statements due to an overstated deferred tax liability. Notably, the FDA approved CYFENDUSTM, an anthrax vaccine, and the company launched NARCAN Nasal Spray Over-The-Counter, aimed at addressing opioid crises. Despite some business achievements, the company has incurred significant restructuring expenses as it works to streamline operations.
Read more →EBSCountermeasures Season 1 Episode 3 Podcast Transcript: Supporting Patients and Families in Crisis
In the latest episode of Countermeasures, Jessica Hulsey and Shannon McLoughlin discuss the ongoing opioid crisis and the challenges faced by patients and families. They highlight the importance of reducing stigma, improving access to care, and implementing innovative treatment programs. The conversation emphasizes the need for holistic approaches and multidisciplinary teams to effectively support individuals struggling with substance use disorders.
Read more →EBS▼ -6.2%on this news
Countermeasures Season 1 Episode 2 Podcast Transcript: Networks of Support
The podcast episode discusses the critical role of community support in recovery from opioid dependency. Amanda Scott from the Detroit Recovery Project shares insights on holistic approaches to treatment, emphasizing the need for mentorship and resources. Personal narratives highlight the impact of the opioid crisis on families and the importance of harm reduction strategies.
Read more →EBSEmergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
Emergent BioSolutions Inc. will host a conference call on November 2, 2023, to discuss its financial results for the third quarter of 2023. The call will cover recent business developments and provide a financial outlook for the full year 2023. Participants can join via webcast or telephone, with registration required for telephone access. A replay will be available on the company's Investors page.
Read more →EBSCountermeasures Season 1 Episode 1 Podcast Transcript: Responding to Opioid Overdose Emergencies
The first episode of the 'Countermeasures' podcast focuses on the opioid crisis, featuring personal stories of loss and recovery. Crystal, a mother, shares her experience with her son's overdose and emphasizes the importance of Naloxone in saving lives. Experts discuss the signs of overdose and the need for public education on opioid risks and Naloxone accessibility. The episode aims to raise awareness and reduce stigma around addiction.
Read more →EBS▼ -7.1%on this news
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
Emergent BioSolutions has appointed Neal Fowler and Don DeGolyer to its Board of Directors, effective October 1, 2023. Both appointees bring over 70 years of combined experience in the biopharmaceutical field. Fowler currently serves as the CEO of Pathalys Pharma and has a history of leadership in prominent firms such as Liquidia Corporation and Johnson & Johnson. DeGolyer has held significant roles in companies like Vertice Pharma and Endo International, contributing to specialty pharmaceuticals and generics.
Read more →EBS▲ +11.5%on this news
Emergent BioSolutions’ NARCAN Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
Emergent BioSolutions announced the over-the-counter launch of its NARCAN Naloxone HCl Nasal Spray 4 mg, set to become available in stores and online nationwide beginning September. This product is intended to provide immediate aid in opioid overdose situations, addressing the urgent public health crisis caused by synthetic opioids. The price for the spray will be $44.99 per carton, but has been lowered to $41.00 for public interest programs, ensuring broader access for at-risk communities. Emergent emphasizes its ongoing commitment to naloxone distribution and public awareness amid rising overdose statistics.
Read more →EBSDocument EMERGENT BIOSO LUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2023 Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56M Updates FY 2023 gui
Emergent BioSolutions Inc. reported its financial results for the second quarter of 2023, showing total revenues of $338 million. While this figure surpassed prior guidance, the company also reported a net loss of $261 million and an impairment charge of $306.7 million linked to its contract development and manufacturing (CDMO) unit. The company announced strategic adjustments, including a focus shift away from CDMO growth and the FDA's approval of a new anthrax vaccine, CYFENDUSTM. Furthermore, an interim CEO has been appointed following the retirement of the former CEO.
Read more →EBSEmergent BioSolutions Reports Financial Results for Second Quarter 2023
Emergent BioSolutions reported its Q2 2023 financial results, highlighting total revenues of $338 million, which surpassed projections despite a significant net loss of $261 million. The company is refocusing its strategy by reducing its emphasis on the CDMO business and announced the FDA approval of its anthrax vaccine, CYFENDUSTM. However, it faced a $306.7 million impairment charge, reflecting a decline in asset values. Additionally, revenues year-to-date have dropped 9% compared to last year's figures.
Read more →EBSEmergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
Emergent BioSolutions is taking strategic steps to enhance its core business by reducing investments in its CDMO services, leading to operational reductions at facilities in Baltimore and Canton. The move aims to improve efficiency and achieve annual cost savings exceeding $100 million. While the company maintains operations in alignment with increased demand for its core products such as NARCAN Nasal Spray, these changes will result in approximately 400 job losses and the elimination of the COO role. This restructuring reflects a focused strategy on key medical countermeasures for public health.
Read more →EBSEmergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
Emergent BioSolutions has been awarded a 10-year contract by BARDA, potentially worth up to $704 million, for the advanced development and procurement of Ebanga™ treatment for Ebola. This contract includes a base performance period and additional options for procurement, focusing on enhancing the medical response to Ebola outbreaks. The collaboration underscores the importance of preparedness against public health threats. Emergent aims to expand the treatment's availability while ensuring rigorous development and safety standards are met.
Read more →EBSEmergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
Emergent BioSolutions Inc. will host a conference call on August 8, 2023, to discuss its financial results for the second quarter of 2023. The call will also touch on recent business developments and provide revenue guidance for the third quarter and full year. Participants can join via webcast or telephone after registering in advance. A replay of the call will be available on the company’s investors page.
Read more →EBSEmergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
Emergent BioSolutions has received FDA approval for CYFENDUS™ (formerly AV7909), an anthrax vaccine designed for post-exposure prophylaxis in adults ages 18 to 65. The approval underscores the vaccine's role in countering biosecurity threats and follows extensive collaboration with U.S. governmental health agencies. While its efficacy is supported by animal studies, specific concerns arise regarding allergic reactions and immune response in immunocompromised patients. Emergent will transition CYFENDUS™ into post-approval procurement, maintaining supply for public health emergencies.
Read more →EBS▼ -9%on this news· ran to -21% by day 3
Emergent BioSolutions Announces CEO Transition
Emergent BioSolutions has announced the retirement of its President and CEO, Robert G. Kramer Sr., effective immediately. Haywood Miller has been appointed as the interim CEO while the company conducts a search for a permanent successor. Kramer will act as an advisor until August 1, 2023, ensuring a smooth transition. The leadership change is part of a broader transformation strategy for the company, as it focuses on executing key objectives and enhancing shareholder value.
Read more →EBSEmergent s Statement Regarding its Amended Credit Agreement GAITHERSBURG, Md.
Emergent BioSolutions (NYSE: EBS) has amended and extended the maturity of its existing syndicated credit agreement, aiming to stabilize and strengthen its core business. This move follows organizational changes and the recent sale of its travel health business to Bavarian Nordic. The company is optimistic about its strategy for sustainable growth and enhancing financial stability, enabling better focus on commitments, including the launch of the NARCAN Nasal spray.
Read more →EBSEmergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
Emergent BioSolutions has completed the sale of its travel health business to Bavarian Nordic for $270 million, with potential further payments of up to $110 million. The deal includes the rights to licensed vaccines for typhoid and cholera, as well as a chikungunya vaccine candidate. This transaction enables Emergent to concentrate on its core products and contract manufacturing, while the majority of its employees supporting these products will transition to Bavarian Nordic. Wells Fargo Securities served as financial advisor for this transaction.
Read more →EBSEmergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
Emergent BioSolutions Inc. announced its 2023 Annual Meeting of Stockholders will occur in a virtual format on May 25, 2023, at 9:00 AM EDT. Eligible stockholders will be able to participate by logging in with a Control Number, allowing them to ask questions during the meeting. Those without a Control Number can listen in but won't have voting privileges. Detailed instructions for attendance and participation are available on the company’s website. A replay of the audio webcast will also be available post-event.
Read more →EBS▲ +6.4%on this news· ran to +19% by day 1shared move
Emergent BioSolutions Reports Financial Results For First Quarter 2023
Emergent BioSolutions Inc. announced its financial results for Q1 2023, reporting revenues of $165 million, which was above prior guidance but reflects a 46% decline from the previous year. The company faced a net loss of $183 million and anticipates further challenges, despite receiving Notices of Intent for medical countermeasures from the U.S. government and planning the sale of its travel health business. Other highlights include strategic discussions with lenders and the upcoming launch of Narcan as an over-the-counter product.
Read more →EBS▲ +6.4%on this news· ran to +19% by day 1shared move
Document EMERGENT BIOSO LUTIONS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2023 Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M Updates FY
Emergent BioSolutions reported its first-quarter financial results for 2023, revealing total revenues of $165 million, which were above prior guidance. However, the company experienced a significant net loss of $183 million and negative adjusted EBITDA of $101 million. The company received notices of intent from the U.S. government for medical countermeasures and announced steps to stabilize its operations, including the impending sale of its travel health business. Additionally, Emergent highlighted the expected launch of an over-the-counter Narcan Nasal Spray this summer.
Read more →EBSEmergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
Emergent BioSolutions Inc. will hold a conference call on May 9, 2023, to discuss its first quarter 2023 financial results. During the call, the company will also cover recent business developments and provide revenue guidance for the second quarter and full year. This event highlights the company's commitment to keeping its investors informed about its financial health and prospects.
Read more →EBSDocument EMERGENT BIOSO LUTIONS REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER 2022 Reports Q4 2022 total revenues of $331M resulting in FY 2022 total revenues of $1,121M, in line with prior guidance Reports Q4 2022 net lo
Emergent BioSolutions reported its financial results for Q4 2022, revealing total revenues of $331 million and a net loss of $88 million. While revenues are in line with prior guidance, they represent a 54% decrease compared to Q4 2021 figures. The company expects revenues to stabilize around $1.15 billion for FY 2023, also forecasting improved adjusted EBITDA. Despite these projections, significant declines in key product sales, particularly in anthrax and smallpox vaccines, raise concerns about the company's financial recovery post-pandemic.
Read more →EBSEmergent BioSolutions Reports Financial Results for Fourth Quarter 2022
Emergent BioSolutions reported its financial results for Q4 and FY 2022, revealing a total revenue of $331M for the fourth quarter, a decrease of 54% from the previous year. The company also recorded a net loss of $88M for Q4 2022 and a total net loss of $224M for the year. The outlook for FY 2023 is cautiously optimistic, with projected revenues of $1,150M and an adjusted EBITDA target of $100M, attributed to anticipated operational improvements. Additionally, positive announcements include the FDA accepting NARCAN for OTC treatment and an agreement to sell the travel health business to Bavarian Nordic for $380 million.
Read more →EBS▲ +12.5%on this news
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN (naloxone HCI) Nasal Spray for Over-the-Counter Use
Emergent BioSolutions announced that the FDA's Nonprescription Drugs Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee voted unanimously in favor of NARCAN Nasal Spray for over-the-counter use. This vote supports the transition of NARCAN from prescription to nonprescription status, highlighting its importance in addressing the opioid overdose crisis in the U.S. The FDA is expected to consider this recommendation by the Prescription Drug User Fee Act goal date of March 29, 2023.
Read more →EBS▲ +12.5%on this news
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
Emergent BioSolutions has announced the sale of its travel health business to Bavarian Nordic for up to $380 million. The transaction includes the rights to vaccines for typhoid and cholera, as well as a chikungunya vaccine candidate. This move allows Emergent to concentrate on its core business areas, including medical countermeasures. The deal is expected to close in the second quarter of 2023, contingent on regulatory approvals and standard closing conditions.
Read more →EBSEmergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
Emergent BioSolutions Inc. has announced that it will host a conference call on February 27, 2023, to discuss its financial results for the fourth quarter of 2022. Participants will be able to access the call via live webcast or telephone after registering in advance. The call aims to provide insights into recent business developments and the financial outlook for the full year of 2023.
Read more →EBSEmergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
Emergent BioSolutions announced a strategic realignment to enhance its core capabilities in medical countermeasures and commercial products. The organizational shake-up includes the appointment of new leadership and the creation of a unified Science and Development function. However, the restructuring will lead to the elimination of 132 positions and significant expected losses as indicated in the preliminary financial results for 2022. The company anticipates that these changes could yield over $60 million in annual savings, establishing a clearer focus on its primary business areas.
Read more →EBSEmergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
Emergent BioSolutions Inc. announced a $379.6 million contract with the U.S. Department of Defense to supply RSDL (Reactive Skin Decontamination Lotion Kit). This contract, which includes a base year and four option renewals, highlights Emergent's long-standing role in providing medical countermeasures for chemical and biological threats. The RSDL has been in use by military personnel for 13 years and is recognized for its effectiveness in decontaminating skin from harmful agents. This award further solidifies Emergent's position in the defense sector and its partnership with the Canadian Commercial Corporation.
Read more →EBSEmergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN (naloxone HCl) Nasal Spray
Emergent’s supplemental new drug application is the first prescription-to-over-the-counter switch application in history to be granted Priority Review by the FDA. NARCAN® (naloxone HCI) Nasal Spray 4 mg, the first intranasal form of naloxone approved by the FDA in 2015, is desig
Read more →EBS▼ -14.5%on this news
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
GAITHERSBURG, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today a research award by the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate efficacy of the company’s single-dose chikung
Read more →EBSEmergent BioSolutions Reports Financial Results For Third Quarter 2022
GAITHERSBURG, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2022. “For more than 20 years, Emergent has been a dependable partner to customers, including the U.S. and allie
Read more →EBSDocument EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2022 GAITHERSBURG, Md.
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2022 GAITHERSBURG, Md., November 8, 2022-Emergent BioSolutions Inc. (NYSE EBS) today reported financial results for the third quarter ended September 30, 2022. "For more than 20 years, Emergent has been a dependa
Read more →EBSEmergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
GAITHERSBURG, Md., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company’s adjuvanted single dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate i
Read more →EBSEmergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2022, recent business developments, and financia
Read more →EBSEmergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
GAITHERSBURG, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® (brincidofovir), the first oral antiviral approved by the U.S. Food and Drug Administration
Read more →EBSEmergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate
Read more →EBSEmergent BioSolutions to Participate in Investor Conferences
GAITHERSBURG, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: 12th Annual Midwest IDEAS Investor Conference August 24, 2
Read more →EBSDocument EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2022 Reports strong core products segment performance offset by impact of continuing post-COVID transition and re-baselining of CDMO services se
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2022 Reports strong core products segment performance offset by impact of continuing post-COVID transition and re-baselining of CDMO services segment Resumes financial guidance provides update to full year 2022
Read more →EBSEmergent BioSolutions Reports Financial Results for Second Quarter 2022
Reports strong core products segment performance offset by impact of continuing post-COVID transition and re-baselining of CDMO services segment Resumes financial guidance; provides update to full year 2022 outlook GAITHERSBURG, Md., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Emergent B
Read more →EBSEmergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022
GAITHERSBURG, Md., July 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, August 1, 2022, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2022, recent business developments, revenue guidan
Read more →EBSEmergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola
GAITHERSBURG, Md. and MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement with Ridgeback Biotherapeutics (“Ridgeback Bio”), a biotechnology company focused on emerging infectious diseases, intended
Read more →EBSEmergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors
GAITHERSBURG, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s board of directors appointed Sujata Dayal as a Class II director to serve on the board effective July 15, 2022, with an initial term expiring at the 2023
Read more →EBSEmergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
GAITHERSBURG, Md., June 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted). AV7909 is the
Read more →EBSEmergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
GAITHERSBURG, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that two-year persistence data from its phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particl
Read more →EBSEmergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
Expands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threat Transaction to be funded with currently available funds; Expected to be accretive beginning with anticip
Read more →EBSEmergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 26, 2022 at 9:00 AM EDT. HOW TO PARTICIPATE IN TH
Read more →EBSDocument EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2022 Reports Q1 2022 total revenues of $308M, in line with guidance, and Adjusted EBITDA of $36M Temporarily suspends CDMO guidance pending furth
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2022 Reports Q1 2022 total revenues of $308M, in line with guidance, and Adjusted EBITDA of $36M Temporarily suspends CDMO guidance pending further clarity on COVID-19 vaccine requirements GAITHERSBURG, Md., Ap
Read more →EBSEmergent BioSolutions Reports Financial Results For First Quarter 2022
Reports Q1 2022 total revenues of $308M, in line with guidance, and Adjusted EBITDA of $36M Temporarily suspends CDMO guidance pending further clarity on COVID-19 vaccine requirements GAITHERSBURG, Md., April 28, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) t
Read more →EBSEmergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2022, recent business developments, revenue guid
Read more →EBSEmergent BioSolutions Provides Corporate Governance Update
Zsolt Harsanyi, Ph.D. Appointed Chairman of the Board Keith Katkin Appointed to the Board Eliminates Role of Executive Chairman Appoints New Chairs of Audit, Strategic Operations, and Scientific Review Committees GAITHERSBURG, Md., March 23, 2022 (GLOBE NEWSWIRE) -- Emergent
Read more →EBS▼ -7.7%on this newsshared move
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
GAITHERSBURG, Md., March 11, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite (SI
Read more →EBSDocument EMERGENT BIOSO LUTIONS REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER 2021 Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and Adjusted EBITDA of
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER 2021 Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and Adjusted EBITDA of $518M, in line with prior guidance Updates full year 2022 guidance
Read more →EBSEmergent BioSolutions Reports Financial Results for Fourth Quarter 2021
Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and Adjusted EBITDA of $518M, in line with prior guidance Updates full year 2022 guidance; provides guidance on Q1 2022 total revenues GAITHERSBURG, Md., Feb. 24,
Read more →EBSEmergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
GAITHERSBURG, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the financial results for the fourth quarter 2021, recent business developments, financial out
Read more →EBSEmergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA margin of 21.5% at the midpoint Reports preliminary 2021 total revenues of $1.78
Read more →EBSEmergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza
Read more →EBSEmergent BioSolutions Reports Financial Results For Third Quarter 2021
GAITHERSBURG, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2021. "Emergent's core products and service businesses remain strong as evidenced by our accomplishments this qu
Read more →EBSDocument EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2021 GAITHERSBURG, Md.
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2021 GAITHERSBURG, Md., November 4, 2021-Emergent BioSolutions Inc. (NYSE EBS) today reported financial results for the third quarter ended September 30, 2021. Emergent's core products and service businesses rema
Read more →EBSEmergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
GAITHERSBURG, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 4, 2021 at 5:00 pm eastern time to discuss the financial results for the third quarter of 2021, recent business developments, and financia
Read more →EBSEmergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus (CHIKV) virus-like parti
Read more →EBSEmergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021 GAITHERSBURG, Md. and CALGARY, Alberta, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) and Provid
Read more →EBSEmergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
NIAID has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), for potential treatment of COVID-19 in adult patients at risk of progression to severe disease GAIT
Read more →EBSEmergent BioSolutions Reports Financial Results For Second Quarter 2021
Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2021. “Our second quarter performance demonstrates the st
Read more →EBSEmergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bul
Read more →EBSDocument EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2021 Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md.
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2021 Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md., July 29, 2021-Emergent BioSolutions Inc. (NYSE EBS) today reported financial results for the second quarter ended June 30, 2021.
Read more →EBSEmergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidan
Read more →EBSEmergent BioSolutions, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit
Investors with losses are encouraged to contact the firm before June 18, 2021; click here to submit trade information LOS ANGELES, June 15, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Emergent BioSolutio
Read more →EBSEmergent BioSolutions, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses are encouraged to contact the firm before June 18, 2021; click here to submit trade information LOS ANGELES, May 27, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Emergent BioSolution
Read more →EBSEmergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dose r
Read more →EBSEmergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT. HOW TO PARTICIPATE IN TH
Read more →EBSDocument EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2021 Revises 2021 Financial Forecast GAITHERSBURG, Md.
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2021 Revises 2021 Financial Forecast GAITHERSBURG, Md., April 29, 2021-Emergent BioSolutions Inc. (NYSE EBS) today reported financial results for the quarter ended March 31, 2021. FINANCIAL HIGHLIGHTS (1) (in m
Read more →EBSEmergent BioSolutions Reports Financial Results for First Quarter 2021
Revises 2021 Financial Forecast GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter ended March 31, 2021. FINANCIAL HIGHLIGHTS (1) (in millions) Q1 2021 Q1 2020 % Change Total revenues $3
Read more →EBSEmergent BioSolutions, Inc. Investors: Company Investigated by the Portnoy Law Firm
LOS ANGELES, April 21, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Emergent BioSoutions, Inc. ("Emergent" or the "Company") (NYSE: EBS) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of inves
Read more →EBSEmergent BioSolutions Investors With Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.
PHILADELPHIA, April 19, 2021 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) to determine whether the Company engaged in securities fraud or other
Read more →EBSEmergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
GAITHERSBURG, Md., April 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the financial results for the first quarter of 2021, recent business developments, revenue guida
Read more →EBSEmergent BioSolutions Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Emergent BioSolutions
NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent BioSolutions” or the “Company”) (NYSE: EBS). On March 31, 2021, after market, reports emerged that
Read more →EBSEmergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson’s COVID-19 Vaccine
HHS has increased Emergent’s task order by $23 million to purchase additional biologics manufacturing equipment Reaffirms 2021 financial guidance GAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continu
Read more →EBSEmergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19
GAITHERSBURG, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) for the treatment of hospitalized patients with COVID-19. The P
Read more →EBSDocument EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2020 Reports record fourth quarter and year to date 2020 performance, in line with prior guidance Reaffirms full year 2021 forecas
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2020 Reports record fourth quarter and year to date 2020 performance, in line with prior guidance Reaffirms full year 2021 forecast GAITHERSBURG, MD., February 18, 2021-Emergent BioSolutions Inc.
Read more →EBSEmergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
Reports record fourth quarter and year to date 2020 performance, in line with prior guidance Reaffirms full year 2021 forecast GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year e
Read more →EBSEmergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021
GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2020, recent business developments,
Read more →EBSEmergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results
Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases year-over-year Reports preliminary 2020 total revenues of $1.55 billion at the midpoint
Read more →EBSEmergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis
GAITHERSBURG, Md. and NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate Emergent’s COVID-19 Human Hyperimmune Globulin (COVID-HIG) product candidate in the fir
Read more →EBSDocument EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2020 AND UPDATES FULL YEAR 2020 GUIDANCE Reports strong third quarter and record year to date performance Upd
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2020 AND UPDATES FULL YEAR 2020 GUIDANCE Reports strong third quarter and record year to date performance Updates full year guidance - refines revenue ranges and raises profita
Read more →EBSEmergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance
Reports strong third quarter and record year to date performance Updates full year guidance — refines revenue ranges and raises profitability ranges GAITHERSBURG, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for
Read more →EBSEmergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020
GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2020, recent business developments, revenue gu
Read more →EBSEmergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19
NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19 Emergent is pl
Read more →EBSEmergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day
GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it is teaming up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and Mothers Against Prescription Drug Abuse (MAPDA) to highlight the importance of po
Read more →EBSEmergent BioSolutions Announces Appointment of Marvin White to the Company’s Board of Directors
GAITHERSBURG, Md., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s board of directors appointed Marvin L. White as a Class II director to serve on the board effective October 1, 2020, with an initial term expiring at the
Read more →EBSEmergent BioSolutions to Participate in Virtual Investor Conferences
GAITHERSBURG, Md., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following virtual investor conferences through the end of September 2020: 2020 NYSE Healthc
Read more →EBSEmergent BioSolutions Announces FDA Approval of NARCAN (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf life of NARCAN® (naloxone HCl) Nasal Spray from 24 months to 36 months. Narcan Nasa
Read more →EBSEmergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028 GAITHERSBURG, Md.
Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028 GAITHERSBURG, Md., August 7, 2020-Emergent BioSolutions Inc. (NYSE:EBS) (the "Company") announced today that it has completed its previously announced offering of $450
Read more →EBSEmergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028
GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the “Notes”), representing an increase
Read more →EBSEmergent BioSolutions Announces Proposed Offering of $400 Million of Senior Unsecured Notes
GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it intends to offer $400 million aggregate principal amount of senior unsecured notes with an expected maturity date of August 2028 (the “Notes”). The N
Read more →EBSebs20200630exhibit99earn EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2020 AND REVISES UPWARD FULL YEAR 2020 GUIDANCE Establishes key collaborations with industry, U.S.
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2020 AND REVISES UPWARD FULL YEAR 2020 GUIDANCE Establishes key collaborations with industry, U.S. government, and health care providers to help advance COVID-19 vaccine and therapeut
Read more →EBSEmergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance
Establishes key collaborations with industry, U.S. government, and health care providers to help advance COVID-19 vaccine and therapeutic solutions Current quarter and year-to-date performance reflect strength of core medical countermeasure business and increased impact of CDMO
Read more →EBSEmergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate
Emergent will provide contract development and manufacturing services beginning in 2020 to produce drug substance at large scale for commercial supply Agreement is valued at approximately $174 million through 2021 and brings the total AstraZeneca commitment to $261 million Part
Read more →EBSEmergent BioSolutions Inc. to be Added to the S&P MidCap 400 Index
GAITHERSBURG, Md., July 21, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Standard & Poor’s (S&P) has indicated that the company will be added to the S&P MidCap 400® index, effective prior to the open of trading on Friday, July 24. The compa
Read more →EBSEmergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020
GAITHERSBURG, Md., July 16, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 30, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2020, recent business developments, revenue guid
Read more →EBSEmergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large scale for commercial manufacturing with first two years valued at approximately $480 million For the remaining three years beginning in 2023, Emergent will
Read more →EBSEmergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
Company acquires property adjacent to its Canton, Massachusetts live viral drug substance development and manufacturing facility to increase campus footprint and build out advanced therapy capability Advanced therapy CDMO drug substance manufacturing services expected to be avai
Read more →EBSEmergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate
Emergent will provide contract development and manufacturing services and secure large-scale manufacturing capacity through 2020 to support AstraZeneca’s COVID-19 vaccine candidate Agreement valued at approximately $87 million GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) -
Read more →EBSEmergent BioSolutions Statement on U.S. District Court Decision
GAITHERSBURG, Md., June 05, 2020 (GLOBE NEWSWIRE) -- Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of the Defendants, Teva Pharmace
Read more →EBSEmergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid domestic production of leading COVID-19 vaccine candidates through 2021 Emergent will provide molecule-to-market CDMO services and commit manufacturing ca
Read more →EBSEmergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 21, 2020 at 9:00am EDT
GAITHERSBURG, Md., May 07, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 21, 2020 at 9:00 AM EDT. The Company, which disclo
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2020
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2020 GAITHERSBURG, Md., April 30, 2020-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the three months ended March 31, 2020. "Emergent is uniquely positioned to respond to the unprecedented
Read more →EBSEmergent BioSolutions Reports Financial Results for First Quarter 2020
Reaffirms full year 2020 financial forecast Executes multi-faceted response to COVID-19 drawing upon longstanding investments in capabilities to address public health threats, as well as expertise in vaccines, therapeutics, and contract development and manufacturing GAITHERSBUR
Read more →EBSEmergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
Emergent will provide contract development and manufacturing services to support Johnson & Johnson’s commitment of one billion doses of vaccine for worldwide emergency pandemic use Agreement valued at approximately $135 million GAITHERSBURG, Md., April 23, 2020 (GLOBE NEWSWIRE)
Read more →EBSEmergent BioSolutions Appoints Dr. Karen L. Smith as Chief Medical Officer
GAITHERSBURG, Md., April 21, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Dr. Karen L. Smith, M.D., Ph.D. as chief medical officer with responsibility for leading and further establishing Emergent’s global integrated capabilit
Read more →EBSEmergent BioSolutions to Release First Quarter 2020 Financial Results and Conduct Conference Call on April 30, 2020
GAITHERSBURG, Md., April 16, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2020, recent business developments, revenue gui
Read more →EBSEmergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs
GAITHERSBURG, Md., April 06, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Nina DeLorenzo to the position of senior vice president for global public affairs. DeLorenzo will oversee external relations, corporate communications,
Read more →EBSEmergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
BARDA to provide $14.5 million in funding to support development of COVID-Human Immune Globulin (COVID-HIG), a human plasma-derived therapy candidate being developed as a potential treatment for COVID-19 in severe hospitalized and high-risk patients NIAID to include COVID-HIG pr
Read more →EBSEmergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™
CDMO agreement for NanoFlu to support pathway to licensure Expanded collaboration now includes NanoFlu and COVID-19 vaccine candidate GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement with Novavax, Inc. (NAS
Read more →EBSEMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE
GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-marke
Read more →EBSEmergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease
Human polyclonal hyperimmune with antibodies to SARS-CoV-2 (COVID-HIG) being developed as a potential treatment for severe hospitalized patients and protection for at-risk individuals Equine-derived polyclonal hyperimmune with antibodies to SARS-CoV-2 (COVID-EIG) being developed
Read more →EBSEmergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease
GAITHERSBURG, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent will collaborate with Novavax, utilizing its molecule-to-market contract development
Read more →EBSEmergent BioSolutions Selects Axiom Fusion eClinical Suite as Its Global eClinical Suite
TORONTO, March 04, 2020 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions (NYSE: EBS), a global life sciences company whose mission is to protect and
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2019
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2019 GAITHERSBURG, MD., February 20, 2020-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2019. FINANCIAL HIGHLIGHTS (in millions) Q4
Read more →EBSEmergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2019
GAITHERSBURG, Md., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2019. FINANCIAL HIGHLIGHTS (in millions) Q4 2019 (unaudited) Q4 2018 (unaudited) $ Change % Change Total Revenues $
Read more →EBSEmergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020
GAITHERSBURG, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 20, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full year 2019, recent business development
Read more →EBSEmergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency
GAITHERSBURG, Md., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for the approval of the company’s single-dos
Read more →EBSEmergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast
Full year 2019 preliminary revenues and adjusted profitability metrics in line with prior guidance Full year 2020 forecast reflects continued growth of core business as well as investments in key development programs and operational capabilities GAITHERSBURG, Md., Jan. 13, 2020
Read more →EBSEmergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
GAITHERSBURG, Md., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed development plan for its chikungunya virus virus-like particle (CHIKV VLP) vaccine c
Read more →EBSEmergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors
GAITHERSBURG, Md., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that two members of its board of directors – Dr. Sue Bailey and Dr. Kathryn C. Zoon – have been recognized as WomenInc. magazine's 2019 Most Influential Corporate Directors
Read more →EBSEmergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
GAITHERSBURG, Md., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV VLP)
Read more →EBSEmergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day
GAITHERSBURG, Md., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today outlined its growth strategy over the next five years and announced its 2024 financial and operational goals during the company’s Analyst and Investor Day held in New York City. Emer
Read more →EBSEmergent BioSolutions to Host 2019 Analyst and Investor Day
GAITHERSBURG, Md., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will be hosting an analyst and investor day on November 21, 2019 from 8:00 AM EST to 2:00 PM EST in New York City. This event is designed for sellside research analysts and institutional i
Read more →EBSEmergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019
Q3 2019 performance above guidance Full year 2019 financial forecast reaffirmed GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the third quarter and nine months ended September 30, 2019. FINANCIAL HIGH
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2019
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2019 Q3 2019 performance above guidance Full year 2019 financial forecast reaffirmed GAITHERSBURG, Md., November 6, 2019-Emergent BioSolutions Inc. (NYSE: EBS) reported financ
Read more →EBSEmergent BioSolutions to Host 2019 Analyst & Investor Day
GAITHERSBURG, Md., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the company will host an analyst and investor day on November 21, 2019 in New York City. This event, which is designed for sellside research analysts and institutional
Read more →EBSEmergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate
GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME, designation by the Committee f
Read more →EBSEmergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019
GAITHERSBURG, Md., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2019, recent business developments, revenue g
Read more →EBSEmergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder
GAITHERSBURG, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), U.S. Department of Health and Human Servic
Read more →EBSEmergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference
GAITHERSBURG, Md., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Cantor Fitzgerald Global Healthcare Conference 2019 to be held in New York from October 2 to 4
Read more →EBSEmergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense
GAITHERSBURG, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing diazepam (5 mg/mL) to treat nerve agent-induced seizures. Emergen
Read more →EBSEmergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000 , (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile
Reaffirms ACAM2000 as a key component of the U.S. preparedness stance against the threat of smallpox as a biologic weapon Supports the government’s continued efforts and long-term strategy to maintain sufficient quantities of smallpox vaccine to provide a response capability to
Read more →EBSEmergent BioSolutions to Participate in Series of Investor Conferences
GAITHERSBURG, Md., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the third quarter of 2019: Three Part Advisors – Midwes
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2019
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2019 GAITHERSBURG, Md., August 1, 2019-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the second quarter and six months ended June 30, 2019. FINANCIAL HIGHLIG
Read more →EBSEmergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2019
Reaffirms full year 2019 financial forecast and operational goals Provides Q3 2019 revenue forecast of $245M-$275M GAITHERSBURG, Md., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the second quarter and six months ended
Read more →EBSEmergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile
GAITHERSBURG, Md., July 30, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option valued at $261 million to procure doses of AV7909 (anthrax va
Read more →EBSEmergent BioSolutions to Release Second Quarter 2019 Financial Results and Conduct a Conference Call on August 1, 2019
GAITHERSBURG, Md., July 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, August 1, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2019, recent business developments, revenue gui
Read more →EBSEmergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine
GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced approval by the U.S. Food and Drug Administration (FDA) of the Prior Approval Supplement (PAS) submitted by the company for its oral cholera vaccine, Vaxchora® (Cholera Vacc
Read more →EBSEmergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness
GAITHERSBURG, Md., June 03, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approxima
Read more →EBSEmergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe
GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine Vivotif® (Typhoid Vaccine Live Oral Ty21a) in five additional European Union Member St
Read more →EBSEmergent BioSolutions Prepares for Initial Shipments of AV7909 Anthrax Vaccine Candidate into the Strategic National Stockpile
GAITHERSBURG, Md., May 15, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has informed the company that it will begin procuring AV7909 (anthrax vaccine adsorbed with CPG 7909 a
Read more →EBSEmergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 23, 2019 at 9:00 AM EDT; Webcast Will Be Available
GAITHERSBURG, Md., May 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 23, 2019 beginning at 9:00 AM EDT at the Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian B
Read more →EBSEmergent BioSolutions Reports First Quarter 2019 Financial Results
Reaffirms full year 2019 financial forecast and operational goals Provides Q2 2019 revenue forecast of $200M-$220M GAITHERSBURG, Md., May 02, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the three months ended March 31, 2019. F
Read more →EBSEmergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019
GAITHERSBURG, Md., April 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, May 2, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2019, recent business developments, revenue guidan
Read more →EBSEmergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
GAITHERSBURG, Md., April 16, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV-VLP)
Read more →EBSEmergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) following a two-do
Read more →EBSEmergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents
GAITHERSBURG, Md., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the U.S. Department of State to establish a long-term, reliable, and stable supply chain
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2018
EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS GAITHERSBURG, Md., February 21, 2019-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2018. FINANCIAL HIGHLIGHTS (in millions) Q4 201
Read more →EBSEmergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
GAITHERSBURG, Md., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan was a co-founder and principal investor of Adapt Pharma Ltd. an
Read more →EBSEmergent BioSolutions to Release Fourth Quarter and Full Year 2018 Financial Results and Conduct a Conference Call on February 21, 2019
GAITHERSBURG, Md., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 21, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full year 2018, recent business development
Read more →EBSEmergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors
GAITHERSBURG, Md., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Robert G. Kramer, Sr. to the company’s Board of Directors. Mr. Kramer currently serves as Emergent’s president and COO. Effective April 1, 2019, Mr. Krame
Read more →EBSEMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2018 FINANCIAL RESULTS AND PROVIDES 2019 FINANCIAL FORECAST Full year 2018 preliminary performance in line with recently revised guidance Full year 2019 forecast reflects conti
EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2018 FINANCIAL RESULTS AND PROVIDES 2019 GAITHERSBURG, Md., January 7, 2019-Emergent BioSolutions Inc. (NYSE: EBS) today announced selected preliminary unaudited 2018 financial results and its financial forecast for 2019. Daniel J. Ab
Read more →EBSEmergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO
GAITHERSBURG, Md., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO,
Read more →EBSInvestor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.com Media Contact: Lynn Kieffer Vice President, Corporate Communications 240-631-3391 KiefferL@ebsi.
Vice President, Investor Relations Vice President, Corporate Communications EMERGENT BIOSOLUTIONS ANNOUNCES DANIEL J. ABDUN-NABI TO RETIRE AS CEO; ROBERT G. KRAMER, SR. TO BECOME PRESIDENT AND CEO GAITHERSBURG, Md., January 4, 2019 Emergent BioSolutions Inc. (NYSE: EBS) today
Read more →EBSEmergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax™
GAITHERSBURG, Md., Dec. 28, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today the submission of an application to the U.S. Food and Drug Administration (FDA) for potential emergency use of NuThrax™ (anthrax vaccine adsorbed with CPG 7909 adjuvant) in
Read more →EBSEmergent BioSolutions Receives Health Canada Approval of BioThrax (Anthrax Vaccine Adsorbed)
GAITHERSBURG, Md., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its anthrax vaccine, BioThrax® (Anthrax Vaccine Adsorbed). BioThrax is indicated for active immun
Read more →EBSEmergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus
GAITHERSBURG, Md. and SAINT-HERBLAIN, France, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) and Valneva SE (VLA) today announced positive interim results for the Phase 1 study evaluating VLA1601, their vaccine candidate against the Zika virus. The high
Read more →EBSEmergent BioSolutions to Participate in Series of Near-Term Investor Conferences
GAITHERSBURG, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the fourth quarter and early portion of the first quarte
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER AND NINE MONTHS OF 2018 Q3 2018 performance in line with guidance Revises full year 2018 financial forecast to reflect anticipated s
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER AND NINE MONTHS OF 2018 GAITHERSBURG, Md., November 1, 2018-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and nine months ended September 30, 2018. FINANCIAL HIGHLIGHTS (in mi
Read more →EBSEmergent BioSolutions Reports Financial Results for Third Quarter and Nine Months of 2018
Q3 2018 performance in line with guidance Revises full year 2018 financial forecast to reflect anticipated strong full year organic business performance, expected at the higher end of the previous forecast, and impact of PaxVax and Adapt Pharma acquisitions GAITHERSBURG, Md., N
Read more →EBSEmergent BioSolutions to Offer All Public Libraries and YMCAs in the U.S. Free Opioid Awareness Education and NARCAN (naloxone HCl) Nasal Spray
New initiatives make free doses and educational materials available to thousands of public libraries & YMCAs in the U.S. GAITHERSBURG, Md., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced, through its subsidiary Adapt Pharma, the launch o
Read more →EBSInvestor Contact: Robert G. Burrows 240-631-3280 BurrowsR@ebsi.com Media Contacts: Lynn Kieffer 240-631-3391 KiefferL@ebsi.com Thom Duddy 484-532-5470 Thomas.Duddy@adaptpharma.com EMERGENT BIOSOLUTI
Thomas.Duddy@adaptpharma.com EMERGENT BIOSOLUTIONS COMPLETES ACQUISITION OF ADAPT PHARMA AND FLAGSHIP PRODUCT NARCAN (naloxone HCl) NASAL SPRAY GAITHERSBURG, Md., October 15, 2018 Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of Ad
Read more →EBSEmergent BioSolutions Completes Acquisition of Adapt Pharma and Flagship Product Narcan (Naloxone HCI) Nasal Spray
GAITHERSBURG, Md., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Adapt Pharma and its flagship product NARCAN® (naloxone HCl) Nasal Spray, the first and only intranasal form of naloxone approved by
Read more →EBSEmergent BioSolutions to Release Third Quarter 2018 Financial Results and Conduct a Conference Call on November 1, 2018
GAITHERSBURG, Md., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 1, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2018, recent business developments, revenue gu
Read more →EBSEmergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax
GAITHERSBURG, Md., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and em
Read more →EBSEMERGENT BIOSOLUTIONS JOINS EFFORT TO COMBAT NATIONAL PUBLIC HEALTH THREAT FROM OPIOID OVERDOSE THROUGH ACQUISITION OF ADAPT PHARMA AND ITS FLAGSHIP PRODUCT NARCAN (naloxone HCl) NASAL SPRAY Acquisition advances Emergent
EMERGENT BIOSOLUTIONS JOINS EFFORT TO COMBAT NATIONAL PUBLIC HEALTH THREAT FROM OPIOID OVERDOSE THROUGH ACQUISITION OF ADAPT PHARMA AND ITS FLAGSHIP PRODUCT NARCAN (naloxone HCl) NASAL SPRAY GAITHERSBURG, Md., August 28, 2018-Emergent BioSolutions Inc. (NYSE: EBS) announced toda
Read more →EBSEmergent BioSolutions to Acquire Specialty Vaccines Company PaxVax
Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potential Broadens development pipeline with an adenovirus 4/7 vaccine funded by the DoD for military requirements as well as other programs addressing emergin
Read more →EBSEMERGENT BIOSOLUTIONS TO ACQUIRE SPECIALTY VACCINES COMPANY PAXVAX Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potential Broadens development pi
EMERGENT BIOSOLUTIONS TO ACQUIRE SPECIALTY VACCINES COMPANY PAXVAX Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potential Broadens development pipeline with an adenovirus 4/7 vaccine funded by the DoD fo
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER AND SIX MONTHS OF 2018 - Q2 2018 total revenues of $220 million, net income of $50 million - Reaffirms full year 2018 financial forecast and operational
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER AND SIX MONTHS OF 2018 GAITHERSBURG, Md., August 2, 2018-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and six months ended June 30, 2018. FINANCIAL HIGHLIGHTS (in millions,
Read more →EBSEmergent BioSolutions Initiates Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic
ZIKV-IG granted Fast Track designation by the U.S. Food and Drug Administration GAITHERSBURG, Md., July 31, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1 clinical study to evaluate the safety and pharmacokinetics of ZI
Read more →EBSEmergent BioSolutions to Release Second Quarter 2018 Financial Results and Conduct a Conference Call on August 2, 2018
GAITHERSBURG, Md., July 18, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 2, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2018, recent business developments, revenue guid
Read more →EBSEmergent BioSolutions to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
GAITHERSBURG, Md., June 08, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will present a corporate overview and discuss recent business developments during a fireside chat at the Goldman Sachs
Read more →EBSEmergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility
Multi-year investment will support growth of contract development and manufacturing capabilities GAITHERSBURG, Md., June 07, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the beginning of a $50 million expansion to the company’s Camden fill/finis
Read more →EBSEmergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be Available
GAITHERSBURG, Md., May 10, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 24, 2018 beginning at 9:00 AM EDT at the Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Bo
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS - Reaffirms full year 2018 financial forecast and operational goals - Provides Q2 2018 revenue forecast of $205M-$230M GAITHERSBURG, Md.
EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS GAITHERSBURG, Md., May 3, 2018-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and three months ended March 31, 2018. FINANCIAL HIGHLIGHTS (in millions, except per share value)
Read more →EBSEmergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
GAITHERSBURG, Md., April 19, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 3, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2018, recent business developments, revenue guidanc
Read more →EBSEmergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries
GAITHERSBURG, Md., April 12, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the successful completion of the Mutual Recognition Procedure (MRP) for market authorization of BioThrax® (Anthrax Vaccine Adsorbed) in five Concerned Member States (CMS) w
Read more →EBSEMERGENT BIOSOLUTIONS ANNOUNCES EXECUTIVE MANAGEMENT CHANGES THAT ENHANCE EXECUTION OF COMPANY S
EMERGENT BIOSOLUTIONS ANNOUNCES EXECUTIVE MANAGEMENT CHANGES THAT ENHANCE EXECUTION OF COMPANY S GROWTH STRATEGY GAITHERSBURG, Md., March 26, 2018 Emergent BioSolutions Inc. (NYSE: EBS) today announced executive management changes that continue to align its organizational struc
Read more →EBSEmergent BioSolutions to Implement Stock Repurchase Program for up to $50 Million of Its Common Stock
GAITHERSBURG, Md., March 22, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized the company’s management to implement a stock repurchase program for up to $50 million of the company's common stock from time to
Read more →EBSEmergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program
GAITHERSBURG, Md., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a contract award by the Centers for Disease Control and Prevention (CDC) valued at $26 million over 12 months for the continued supply of Vaccinia Immune Globulin Intravenou
Read more →EBSEmergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus
GAITHERSBURG, Md. and LYON, France, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) and Valneva SE (Euronext Paris:VLA) today announced the initiation of a Phase 1 clinical trial in the U.S. to evaluate the safety and immunogenicity of VLA1601, their vacci
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND TWELVE MONTHS 2017 FINANCIAL RESULTS - Reaffirms full year 2018 forecast and 2020 goals - Revises 1Q 2018 forecast GAITHERSBURG, Md.
EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND TWELVE MONTHS 2017 FINANCIAL RESULTS GAITHERSBURG, Md., February 22, 2018-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and twelve months ended December 31, 2017. 2017 FINANCIAL HIGHLIGHTS (in
Read more →EBSEmergent BioSolutions to Release Fourth Quarter and Full Year 2017 Financial Results and Conduct a Conference Call on February 22, 2018
GAITHERSBURG, Md., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 22, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2017, recent business
Read more →EBSEMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018
EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 FINANCIAL OUTLOOK GAITHERSBURG, Md., January 8, 2018-Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary unaudited 2017 financial results and guidance for 2018. Daniel J. Abdun-N
Read more →EBSEmergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
GAITHERSBURG, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 dose ranging study to evaluate the safety, pharmacokinetics, and clinical benefit of FLU-IGIV, the company’s anti-influenza immune globulin being
Read more →EBSEmergent BioSolutions to Participate in First Quarter 2018 Investor Conferences
GAITHERSBURG, Md., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the first quarter of 2018: J.P. Morgan & Co. – 36th Annu
Read more →EBSEmergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government
GAITHERSBURG, Md., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract by the Department of National Defence (DND) valued at approximately $8 million to deliver Anthrasil® (Anthrax Immune Globulin Intravenous
Read more →EBSEmergent BioSolutions to Host 2017 Analyst & Investor Day
GAITHERSBURG, Md., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company will host an analyst and investor day on December 7, 2017 in New York City. This event, which is designed for sellside research analysts and institutional
Read more →EBSEmergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
GAITHERSBURG, Md., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the manufacture of ACAM2000®, (Smallpox (Vaccinia) Va
Read more →EBSInvestor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.com Media Contact: Lynn Kieffer Vice President, Corporate Communications 240-631-3391 KiefferL@ebsi.com EMERGENT BIOSOLUTI
Vice President, Investor Relations Vice President, Corporate Communications EMERGENT BIOSOLUTIONS ANNOUNCES NOTICE OF TERMINATION OF CONVERSION RIGHTS OF 2.875% CONVERTIBLE SENIOR NOTES DUE 2021 GAITHERSBURG, Md., November 14, 2017-Emergent BioSolutions Inc. (NYSE: EBS) announ
Read more →EBSEmergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes Due 2021
GAITHERSBURG, Md., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has issued a Notice of Termination of Conversion Rights for all of its outstanding 2.875% Convertible Senior Notes due 2021 (“Notes”) and has elected to exercise its
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER AND NINE MONTHS 2017 FINANCIAL RESULTS; RAISES CALENDAR YEAR 2017
EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER AND NINE MONTHS 2017 FINANCIAL RESULTS; RAISES CALENDAR YEAR 2017 GUIDANCE GAITHERSBURG, MD, November 2, 2017-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and nine months ended September 30, 2017.
Read more →EBSEmergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance
GAITHERSBURG, Md., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2017. FINANCIAL HIGHLIGHTS (in millions) 3Q 2017 3Q 2016 (1) Total Revenues $ 149.4 $ 142.9 Net Income $ 33.
Read more →EBSEmergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference Call on November 2, 2017
GAITHERSBURG, Md., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) will release its financial results for the third quarter and nine months of 2017 immediately after market close on Thursday, November 2, 2017. The company will also host a conference call at 5:0
Read more →EBSEmergent BioSolutions Completes Acquisition of ACAM2000 Business From Sanofi
GAITHERSBURG, Md., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Sanofi’s ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) business, which includes ACAM2000, the only smallpox vaccine approved by the
Read more →EBSEmergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to $25 Million to Supply Nerve Agent Antidote Auto-Injector
GAITHERSBURG, Md., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at up to approximately $25 million by the U.S. Department of State to supply TROBIGARD™ (Atropine Sulfate [2mg]/Obidoxime Chloride
Read more →EBSEmergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
Transaction anticipated to be additive by approximately $9 million to revenue and neutral to GAAP net income for full year 2017 GAITHERSBURG, Md., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of rax
Read more →EBSEmergent BioSolutions Announces Closing of New $200 Million Senior Secured Credit Facility
GAITHERSBURG, Md., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed a new five-year, $200 million syndicated senior secured credit facility. This new facility replaces and represents an increase from the Company’s prior
Read more →EBSEmergent BioSolutions to Supply DoD With Chemical Threat Countermeasure RSDL Under Five-Year Follow-On Contract Valued at Up to $171 Million
GAITHERSBURG, Md., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a five-year follow-on contract valued at up to approximately $171 million by the U.S. Department of Defense (DoD) to supply RSDL® (Reactive Skin De
Read more →EBSEmergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure
GAITHERSBURG, Md., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at approximately $63 million by the Biomedical Advanced Research and Development Authority (BARDA) to develop an antidote spray d
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER AND SIX MONTHS 2017 FINANCIAL RESULTS; REAFFIRMS CALENDAR YEAR 2017
EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER AND SIX MONTHS 2017 FINANCIAL RESULTS; REAFFIRMS CALENDAR YEAR 2017 GUIDANCE GAITHERSBURG, MD, August 3, 2017-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and six months ended June 30, 2017. FINAN
Read more →EBSEmergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense
GAITHERSBURG, Md., July 31, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded approximately $23 million to develop a novel multi-drug auto-injector for nerve agent antidote delivery. Emergent’s device is being designed for int
Read more →EBSEmergent BioSolutions Secures Exclusive Worldwide Rights to Valneva’s Zika Vaccine Technology
Parties to collaborate through Phase 1 clinical development Phase 1 trial expected to commence in late 2017 or early 2018 GAITHERSBURG, Md., July 26, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a licensing agreement with Valneva SE for global
Read more →EBSEmergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Call on August 3, 2017
GAITHERSBURG, Md., July 20, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will release its second quarter financial results immediately after market close on Thursday, August 3, 2017. The company will then conduct a conference call at 5:00 pm (Eastern Time) on th
Read more →EBSEmergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
All-cash transaction includes a $76 million upfront payment and up to $20 million in product sale and manufacturing-related milestone payments Addition of licensed anthrax therapeutic expands Emergent’s portfolio of approved medical countermeasures addressing public health threa
Read more →EBSEMERGENT BIOSOLUTIONS TO ACQUIRE ACAM2000 BUSINESS FROM SANOFI Addition of ACAM2000 , the only FDA-licensed smallpox vaccine, expands and diversifies Emergent's portfolio of medical countermeasures and is synergistic wit
EMERGENT BIOSOLUTIONS TO ACQUIRE ACAM2000 BUSINESS FROM SANOFI GAITHERSBURG, Md., July 14, 2017-Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to acquire the ACAM2000 , (Smallpox (Vaccinia) Vaccine, Live) business of Sanofi in an all
Read more →EBSEmergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; Webcast Will be Available
GAITHERSBURG, Md., May 11, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 25, 2017 beginning at 9:00 AM EDT at the Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Bo
Read more →EBSEmergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore
GAITHERSBURG, Md., May 10, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today held a ribbon-cutting ceremony led by Dr. Rick Bright, director of the Biomedical Advanced Research and Development Authority (BARDA), and Daniel J. Abdun-Nabi, Emergent’s president an
Read more →EBSEmergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA
ADVISORY, May 09, 2017 (GLOBE NEWSWIRE) -- WHO: Emergent BioSolutions Inc. (NYSE:EBS) WHAT: Ribbon-cutting and tour of expanded Emergent BioSolutions’ Center for Innovation in Advancement Development and Manufacturing (CIADM), featuring speakers: D aniel J. Abdun-Nabi Presid
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS; REAFFIRMS 2017
EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS; REAFFIRMS 2017 GUIDANCE GAITHERSBURG, MD, May 4, 2017-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and three months ended March 31, 2017. FINANCIAL HIGHLIGHTS (in millions)
Read more →EBSEmergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call on May 4, 2017
GAITHERSBURG, Md., April 20, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 4, 2017 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2017, recent business developments, revenue guidanc
Read more →EBSEmergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botulism Antitoxin
GAITHERSBURG, Md., March 31, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) to manufacture and store bulk drug substance for i
Read more →EBSEmergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic National Stockpile
GAITHERSBURG, Md., March 17, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed a two-year contract with the Biomedical Advanced Research and Development Authority (BARDA), a division within the Office of the Assistant Secretary of P
Read more →EBSInvestor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.com Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3281 SchmittT@ebsi.com EMER
Vice President, Investor Relations Tracey Schmitt Lintott Senior Vice President, Global Public Affairs EMERGENT BIOSOLUTIONS AWARDED $100 MILLION BARDA CONTRACT FOR BIOTHRAX DELIVERIES TO THE STRATEGIC NATIONAL STOCKPILE GAITHERSBURG, Md., March 17, 2017 - Emergent BioSolutio
Read more →EBSEmergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 Goals
GAITHERSBURG, Md., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31, 2016. 2016 FINANCIAL HIGHLIGHTS (1) (2) (in millions) 4Q 2016 CY 2016 Combined & Continuing Operations Bas
Read more →EBSEmergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics
GAITHERSBURG, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $30.5 million to develop monoclonal antibody therap
Read more →EBSEmergent BioSolutions to Release Fourth Quarter and Full Year 2016 Financial Results and Conduct a Conference Call on February 23, 2017
GAITHERSBURG, Md., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 23, 2017 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2016, recent business
Read more →EBSEmergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum Antiviral UV-4B for Dengue
GAITHERSBURG, Md., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b multiple ascending dose study to evaluate the safety and tolerability of UV-4B, the company’s novel antiviral candidate being developed as a pot
Read more →EBSEmergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for Large-Scale Manufacturing of BioThrax
GAITHERSBURG, Md., Jan. 27, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Paul-Ehrlich-Institut (PEI), the regulatory agency under the German Federal Ministry of Health, has approved the company’s large-scale manufacturing facility, Build
Read more →EBSEmergent BioSolutions Announces Preliminary 2016 Financial Results and Provides 2017 Financial Outlook
GAITHERSBURG, Md., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced preliminary unaudited 2016 financial results and guidance for 2017. Daniel J. Abdun-Nabi, president and chief executive officer of Emergent BioSolutions, said, “We are very
Read more →EBSEmergent BioSolutions to Participate in First Quarter 2017 Investor Conferences
GAITHERSBURG, Md., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the first quarter of 2017. 35th Annual J.P. Morgan Healt
Read more →EBSEmergent BioSolutions Receives Health Canada Approval for Botulism Antitoxin
GAITHERSBURG, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its botulism antitoxin, BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)]. B
Read more →EBSEmergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile
Company signs follow-on contract with CDC valued at up to $911 million to supply to the SNS approximately 29.4 million doses of BioThrax through September 2021 BARDA issues notice of intent to separately procure approximately $100 million of BioThrax for the SNS over 24 months f
Read more →EBSInvestor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.com Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3281 SchmittT@ebsi.com
Vice President, Investor Relations Tracey Schmitt Lintott Senior Vice President, Global Public Affairs DR. KATHRYN C. ZOON APPOINTED TO EMERGENT BIOSOLUTIONS BOARD OF DIRECTORS GAITHERSBURG, Md.-November 8, 2016-Emergent BioSolutions Inc. (NYSE:EBS) today announced the appoin
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER AND NINE MONTHS 2016
EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER AND NINE MONTHS 2016 FINANCIAL RESULTS GAITHERSBURG, MD, November 7, 2016-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and nine months ended September 30, 2016. FINANCIAL HIGHLIGHTS The following
Read more →EBSEmergent BioSolutions to Release Third Quarter 2016 Financial Results and Conduct a Conference Call on November 7, 2016
GAITHERSBURG, Md., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will release its financial results for the third quarter on Monday, November 7, 2016 and host a conference call at 5:00 pm (Eastern Time). In the press release and on the conference call, t
Read more →EBSEmergent BioSolutions Provides Update on Status of BioThrax Procurement Contract and Discussions With CDC
GAITHERSBURG, Md., Sept. 30, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the status of its 2011 BioThrax® (Anthrax Vaccine Adsorbed) procurement contract and the status of its discussions with the Centers for Disease Control and Prev
Read more →EBSEMERGENT BIOSOLUTIONS AWARDED BARDA CONTRACT FOR ADVANCED DEVELOPMENT AND DELIVERY OF NUTHRAX, A NEXT GENERATION ANTHRAX VACCINE, VALUED AT UP TO $1.6
EMERGENT BIOSOLUTIONS AWARDED BARDA CONTRACT FOR ADVANCED DEVELOPMENT AND DELIVERY OF NUTHRAX, A NEXT GENERATION ANTHRAX VACCINE, VALUED AT UP TO $1.6 BILLION GAITHERSBURG, Md., September 30, 2016-Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has signed a multi-
Read more →EBSEMERGENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent BioSolutions, Inc. - EBS
NEW ORLEANS, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 19, 2016 to file lead plaintiff applications in a securities class actio
Read more →EBSEmergent BioSolutions Receives FDA Approval for Large-Scale Manufacturing of BioThrax in Building 55
GAITHERSBURG, Md., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for the manufacture of BioThrax® (Anthrax Vacci
Read more →EBSEmergent BioSolutions Announces Conversion Rate Adjustment to 2.875% Convertible Senior Notes Due 2021 Following Spin-Off of Aptevo Therapeutics
GAITHERSBURG, Md., Aug. 12, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that, as a result of the completion of the spin-off of Aptevo Therapeutics, the conversion rate for the company’s 2.875% Convertible Senior Notes due 2021 has been adjusted
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER AND SIX MONTHS 2016
EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER AND SIX MONTHS 2016 FINANCIAL RESULTS GAITHERSBURG, MD, August 4, 2016-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and six months ended June 30, 2016. FINANCIAL HIGHLIGHTS Q2 2016 & RECENT BUSIN
Read more →EBSEmergent BioSolutions Completes Spin-Off of Aptevo Therapeutics
GAITHERSBURG, Md., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed its previously announced spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through the distribution of all of the shares of Aptevo common stock to the
Read more →EBSEMERGENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent BioSolutions, Inc. - EBS
NEW ORLEANS, LA--(Marketwired - July 29, 2016) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 19, 2016 to file lead plaintiff applications in a securities class acti
Read more →EBSExcerpts from the Information Statement of Aptevo Therapeutics Inc., dated
Excerpts from the Information Statement of Aptevo Therapeutics Inc., dated July 22, 2016 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS Agreements with Emergent Following the separation and distribution, Aptevo and Emergent will operate separately, each as an independent
Read more →EBSEmergent BioSolutions to Release Second Quarter 2016 Financial Results and Conduct a Conference Call on August 4, 2016
GAITHERSBURG, Md., July 21, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 4, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2016, provide an update on the status of guidanc
Read more →EBSEmergent BioSolutions Announces Commencement of When Issued Trading of Aptevo Common Stock
GAITHERSBURG, Md., July 20, 2016 (GLOBE NEWSWIRE) -- In connection with the spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through a dividend distribution by Emergent BioSolutions Inc. (NYSE:EBS) of one share of Aptevo common stock for every two shares of Emergent common stoc
Read more →EBSEmergent BioSolutions to Implement Stock Repurchase Program for Up to $50 Million of Its Common Stock
GAITHERSBURG, Md., July 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized the company’s management to implement a stock repurchase program for up to $50 million of the company's common stock from time to
Read more →EBSEmergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 Registration Statement
Aptevo Therapeutics common stock approved for listing on the NASDAQ Global Select Market GAITHERSBURG, Md., July 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Registration Statement on Form 10 filed by Aptevo Therapeutics Inc. has be
Read more →EBSEmergent BioSolutions’ Board of Directors Approves Spin-Off of Aptevo Therapeutics and Sets Record and Dividend Distribution Dates and Distribution Ratio
GAITHERSBURG, Md., July 11, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that, on July 10, 2016, its Board of Directors approved the spin-off of Aptevo Therapeutics Inc. and declared a dividend distribution of one share of Aptevo common stock for
Read more →EBSEmergent BioSolutions Receives BARDA Task Order Valued at Up to $21.9 Million to Develop and Manufacture a Zika Vaccine
GAITHERSBURG, Md., June 27, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Center for Innovation in Advanced Development and Manufacturing (CIADM) has received a task order from the Biomedical Advanced Research and Development Authority (B
Read more →EBSEmergent BioSolutions Receives FDA Orphan Drug Status for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease
GAITHERSBURG, Md., June 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug status for BioThrax® (Anthrax Vaccine Adsorbed) for post-exposure prophylaxis (PEP) of anthrax disea
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Q1 2016 financial performance in line with guidance CDC notifies the Company of its intent to award a follow-on BioThrax procurement contract on
EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS GAITHERSBURG, MD, May 5, 2016-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter ended March 31, 2016. Q1 2016 FINANCIAL HIGHLIGHTS RECENT BUSINESS ACCOMPLISHMENTS "We achieved s
Read more →EBSEmergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be Available
GAITHERSBURG, May 04, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 19, 2016 beginning at 9:00 AM Eastern at the Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814. Foll
Read more →EBSEmergent Biosolutions to Participate in the Bank of America Merrill Lynch Healthcare Conference in May 2016
GAITHERSBURG, Md., April 26, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the Bank of America Merrill Lynch Healthcare Conference, May 10-12, 2016 in Las Vegas, NV. Presen
Read more →EBSEmergent BioSolutions to Release First Quarter 2016 Financial Results and Conduct a Conference Call on May 5, 2016
GAITHERSBURG, Md., April 21, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 5, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2016, recent business developments, revenue guidanc
Read more →EBSEmergent BioSolutions Presents Preclinical Data on ES425 a Bispecific Immunotherapeutic Protein for Triple-Negative Breast Cancer
GAITHERSBURG, Md., April 20, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it presented preclinical data on its bispecific ADAPTIRTM (modular protein technology) molecule, ES425, at the American Association for Cancer Research Annual Meeting
Read more →EBSEmergent BioSolutions Submits sBLA for FDA Approval of Large-Scale Manufacturing of BioThrax in Building 55
GAITHERSBURG, Md., April 18, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of the manufacture of BioThrax® (A
Read more →EBSEmergent BioSolutions Announces Filing of Form 10 Registration Statement for Its Planned Spin-Off of Its Biosciences Business Aptevo Therapeutics
GAITHERSBURG, Md., April 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initial filing of a Form 10 Registration Statement with the U.S. Securities and Exchange Commission in connection with the company's previously announced plan to spin-o
Read more →EBSEmergent BioSolutions to Participate in Needham & Company’s 15th Annual Healthcare Conference in April 2016
GAITHERSBURG, Md., March 30, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in Needham & Company’s 15th Annual Healthcare Conference, April 12-13, 2016 in New York, NY. Present
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND TWELVE MONTHS 2015 FINANCIAL RESULTS AND REAFFIRMS 2016
EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND TWELVE MONTHS 2015 FINANCIAL RESULTS AND REAFFIRMS 2016 OUTLOOK GAITHERSBURG, MD, February 25, 2016-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and twelve months ended December 31, 2015. 2015
Read more →EBSEmergent BioSolutions’ Emergard Auto-Injector Platform for Nerve Agent Antidote Delivery Selected by U.S. Department of Defense and Battelle for Testing and Development
GAITHERSBURG, Md., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that Emergard™, the company’s ruggedized, military-grade auto-injector platform, has been selected by the U.S. Department of Defense (DoD) and Battelle to be tested against
Read more →EBSEmergent BioSolutions to Release Fourth Quarter and Full Year 2015 Financial Results and Conduct a Conference Call on February 25, 2016
GAITHERSBURG, Md., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 25, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2015, recent business
Read more →EBSEmergent BioSolutions Announces Executive Management Team of New Spin-Off Company Aptevo Therapeutics
GAITHERSBURG, Md., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the anticipated executive management team of Aptevo Therapeutics Inc., Emergent’s planned Biosciences business spin-off company. Members of the Aptevo executive management t
Read more →EBSEMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2015 FINANCIAL RESULTS, PROVIDES 2016 FINANCIAL OUTLOOK, AND OUTLINES NEW FIVE-YEAR (2016-2020) STRATEGIC GROWTH PLAN 2015 Preliminary Estimates: o Total revenues of $520 to $5
EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2015 FINANCIAL RESULTS, PROVIDES 2016 FINANCIAL OUTLOOK, AND OUTLINES NEW FIVE-YEAR (2016-2020) STRATEGIC GROWTH PLAN GAITHERSBURG, MD, January 11, 2016- Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary unaudited 2015
Read more →EBSEmergent BioSolutions Receives Favorable IRS Private Letter Ruling in Connection With its Planned Biosciences Business Spin-Off
GAITHERSBURG, Md., Jan. 10, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has received a favorable private letter ruling from the Internal Revenue Service related to the planned spin-off of its biosciences business. Subject to its terms, t
Read more →EBSEmergent BioSolutions Announces Composition of Board of Directors of New Spin-Off Company Aptevo Therapeutics
GAITHERSBURG, Md., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the anticipated composition of the board of directors of Aptevo Therapeutics Inc., which is the name of Emergent’s biosciences business proposed to be spun off into a separa
Read more →EBSEmergent BioSolutions to Participate in First Quarter 2016 Investor Conferences
GAITHERSBURG, Md., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the first quarter of 2016. 34th Annual J.P. Morgan Healt
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER AND NINE MONTHS 2015
EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER AND NINE MONTHS 2015 FINANCIAL RESULTS GAITHERSBURG, MD, November 5, 2015-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and nine months ended September 30, 2015. FINANCIAL HIGHLIGHTS 2015 BUSINESS
Read more →EBSEmergent BioSolutions to Release Third Quarter 2015 Financial Results and Conduct a Conference Call on November 5, 2015
GAITHERSBURG, Md., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, November 5, 2015 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2015, recent business developments, financial o
Read more →EBSEmergent BioSolutions Receives $44 Million CDC Contract to Further Advance Vaccinia Immune Globulin Intravenous Program
GAITHERSBURG, Md., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Centers for Disease Control and Prevention (CDC) has exercised options under contract 200-2012-52242 for the supply of Vaccinia Immune Globulin (VIGIV) into the U.S
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER AND SIX MONTHS 2015 FINANCIAL RESULTS AND REAFFIRMS 2015
EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER AND SIX MONTHS 2015 FINANCIAL RESULTS AND REAFFIRMS 2015 GUIDANCE GAITHERSBURG, MD, August 6, 2015-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and six months ended June 30, 2015. Financial highli
Read more →EBSEmergent BioSolutions Announces Plan to Implement Tax-Free Spin-Off of Biosciences Business Into a Separate Publicly-Traded Company
GAITHERSBURG, Md., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized management to pursue a tax-free spin-off of the company's Biosciences business into a separate, stand-alone publicly-traded company
Read more →EBSEmergent BioSolutions Expands Biodefense Business Through Launch of a Military-Grade Auto-Injector Device for Chemical Threats
GAITHERSBURG, Md., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it is launching a ruggedized, military-grade auto-injector device, known as Emergard , which is designed for intramuscular self-injection of antidotes and other emergenc
Read more →EBSEmergent BioSolutions to Release Second Quarter 2015 Financial Results and Conduct a Conference Call on August 6, 2015
GAITHERSBURG, Md., July 23, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 6, 2015 at 8:00 am (Eastern Time) to discuss the financial results for the second quarter of 2015, recent business developments, financial ou
Read more →EBSEmergent BioSolutions Awarded $19.7 Million BARDA Contract to Develop and Manufacture Ebola Monoclonal Antibodies
GAITHERSBURG, Md., July 20, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) valued at $19.7 million to develop and manufacture cGMP lots of three Eb
Read more →EBSEmergent BioSolutions Signs Long-Term Manufacturing Agreement With Prometic Life Sciences
GAITHERSBURG, Md., May 19, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed a strategic long-term manufacturing agreement with ProMetic Life Sciences Inc. This agreement provides ProMetic access to Emergent's cGMP FDA-licensed biop
Read more →EBSEmergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 21, 2015 at 9:00 AM Eastern; Webcast Will be Available
GAITHERSBURG, Md., May 14, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 21, 2015 beginning at 9:00 AM Eastern at the Hilton Washington DC North, 620 Perry Parkway, Gaithersburg,
Read more →EBSInvestor Contact Robert G. Burrows Vice President, Investor Relations 301-795-1877 BurrowsR@ebsi.com Media Contact: Tracey Schmitt Vice President, Global Public Affairs and Corporate Responsibility 301-795-1800 SchmittT@
Vice President, Investor Relations Vice President, Global Public Affairs and Corporate Responsibility EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS GAITHERSBURG, MD, May 7, 2015 - Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the qu
Read more →EBSEmergent BioSolutions Reports First Quarter 2015 Financial Results
GAITHERSBURG, Md., May 7, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter ended March 31, 2015. Financial highlights for Q1 2015 include: Total revenues of $63.6 million, up 18% versus Q1 2014 Net loss of $21.5 million
Read more →EBSEmergent BioSolutions Expands Commercial Product Portfolio With FDA Approval of IXINITY, a Recombinant Factor IX Treatment for Hemophilia B
GAITHERSBURG, Md., April 30, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved IXINITY [coagulation factor IX (recombinant)], an intravenous recombinant human coagulation factor IX therapeu
Read more →EBSEmergent BioSolutions to Participate in May and June 2015 Investor Conferences
GAITHERSBURG, Md., April 29, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company's senior management team will participate in the following investor conferences in May and June 2015. Credit Suisse Antibody Conference Prese
Read more →EBSInvestor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.com Media Contact: Tracey Schmitt Vice President, Global Public Affairs and Corporate Responsibility 240-631-3394 SchmittT
Vice President, Investor Relations Vice President, Global Public Affairs and Corporate Responsibility EMERGENT BIOSOLUTIONS COMPLETES INVESTIGATION AND RESUMES BIOTHRAX MANUFACTURING ACTIVITIES; RE-AFFIRMS PREVIOUS FULL-YEAR 2015 FINANCIAL OUTLOOK GAITHERSBURG, Md., April 22,
Read more →EBSEmergent BioSolutions Completes Investigation and Resumes BioThrax Manufacturing Activities; Re-Affirms Previous Full-Year 2015 Financial Outlook
Internal investigation completed; implementing targeted corrective and preventive actions Full year 2015 outlook re-affirmed Total revenues of $510-$540 million Net income of $50-$60 million (GAAP) and $60-$70 million (adjusted) Preliminary Q1 2015 revenues anticipated to be
Read more →EBSEmergent BioSolutions Receives FDA Approval of Anthrasil, Its Anthrax Immune Globulin, for Use in the Treatment of Inhalational Anthrax
GAITHERSBURG, Md., March 25, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved Anthrasil [Anthrax Immune Globulin Intravenous (Human)], also known as AIGIV, for treatment of inhalational an
Read more →EBSEmergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine
GAITHERSBURG, Md., March 24, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of NuThraxTM (anthrax vaccine adsorbed wi
Read more →EBSEmergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate
Emergent has completed proof-of concept manufacturing of an MVA Ebola Zaire vaccine candidate anticipated for use in a Phase 1 clinical study in the UK 200L scale production leverages Emergent's unique expertise and capabilities in MVA-based vaccine product development and manuf
Read more →EBSEmergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer
GAITHERSBURG, Md. and MARTINSRIED/MUNICH, Germany, March 9, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) today announced the initiation of a Phase 1 clinical study to evaluate the safety, to
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND TWELVE MONTHS 2014 FINANCIAL RESULTS AND PROVIDES UPDATE ON 2015
EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND TWELVE MONTHS 2014 FINANCIAL RESULTS AND PROVIDES UPDATE ON 2015 OUTLOOK GAITHERSBURG, MD, March 5, 2015-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and twelve months ended December 31, 2014.
Read more →EBSEmergent BioSolutions to Participate in March 2015 Investor Conferences
GAITHERSBURG, Md., Feb. 20, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company's senior management team will participate in the following investor conferences in March 2015: Cowen and Company 35th Annual Health Care Confer
Read more →EBSEmergent BioSolutions Announces Primary Endpoints Met in Pivotal Study Supporting Licensure of Building 55
GAITHERSBURG, Md., Feb. 13, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced completion of the in-life phase of the pivotal nonclinical efficacy study designed to demonstrate that BioThrax (Anthrax Vaccine Adsorbed) manufactured at large scale in the
Read more →EBSEmergent BioSolutions to Release Fourth Quarter and Full Year 2014 Financial Results and Conduct a Conference Call on March 5, 2015
GAITHERSBURG, Md., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, March 5, 2015 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2014, recent business deve
Read more →EBSEMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2014 FINANCIAL RESULTS AND PROVIDES 2015 FINANCIAL OUTLOOK 2014 Preliminary Estimates: Total revenues of $445 to $450 million, a 43% increase over 2013 (at midpoint) GAAP net i
EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2014 FINANCIAL RESULTS AND PROVIDES 2015 FINANCIAL OUTLOOK ROCKVILLE, MD, January 11, 2015-Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary unaudited 2014 financial results and provided guidance for 2015. (I) Prelimi
Read more →EBSEmergent BioSolutions to Participate in January 2015 Investor Conferences
ROCKVILLE, Md., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company's senior management team will participate in the following investor conferences in January 2015: 33rd Annual J.P. Morgan Healthcare Conference Pre
Read more →EBSEmergent BioSolutions Expands Biodefense Franchise; Acquires Portfolio of Broad Spectrum Antibiotics
Lead antibiotic candidate currently under DTRA development contract, valued at up to $15 million, as an oral and IV treatment for Burkholderia pseudomallei as well as other bioterror agents In vitro models have shown activity of EV-035 series of molecules in multi-drug resistant
Read more →EBSEmergent BioSolutions to Webcast Presentation at 25th Annual Oppenheimer Healthcare Conference
ROCKVILLE, Md., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the 25TH Annual Oppenheimer Healthcare Conference in New York on Wednesday, December 10, 2014 at 2:45 PM Eastern. During
Read more →EBSEmergent BioSolutions Seeks Expanded BioThrax Label; Submits FDA Application for Post-Exposure Prophylaxis
ROCKVILLE, Md., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand the label of BioThrax (Anthrax Vaccin
Read more →EBSEMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER AND NINE MONTH 2014
EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER AND NINE MONTH 2014 FINANCIAL RESULTS ROCKVILLE, MD, November 6, 2014-Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and nine months ended September 30, 2014. Financial highlights included: Revised o
Read more →EBSEmergent BioSolutions to Webcast Presentation at Credit Suisse 2014 Healthcare Conference
ROCKVILLE, Md., Oct. 20, 2014 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the Credit Suisse 2014 Healthcare Conference in Phoenix, Arizona on Tuesday, November 11, 2014 at 8:00 AM Mountain. Duri
Read more →Competitive Position
How EBS ranks across every disease it competes inCompetitive Position is a premium feature
See how EBS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial